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Abstract 
 
 
Blood coagulation factor VIII (FVIII) is a non-enzymatic protein cofactor, which plays a 
crucial role in the formation of a stable blood clot. Absence or deficiency of FVIII results in the 
blood disorder hemophilia A, with symptoms including internal hemorrhaging and the inability to 
stop bleeding from open wounds. Treatment of hemophilia A relies on replacement of FVIII with 
blood, plasma, or protein concentrate infusions. Unfortunately, approximately 30% of patients 
receiving replacement FVIII generate pathologic anti-FVIII inhibitory antibodies, which both 
reduce the effectiveness of the FVIII therapeutic and increase the severity of hemophilia A 
symptoms. 
This thesis reports the determination of the molecular structure for “Et3i”, a next-
generation human/porcine chimeric FVIII protein for hemophilia A therapy. At 3.2 Å resolution 
with a Rwork of 0.2146 and Rfree of 0.2879, this will be the highest resolution structure of FVIII to 
date and will be of substantial interest to the hematological community. Furthermore, an improved 
model of human FVIII with more robust geometry and amino acid register assignment, and a Rwork 
of 0.2655, and Rfree of 0.2895 based on previous 3.7 Å data has been constructed. Lastly, progress 
has been made towards the structural determination of the inhibitory antibodies M6143, 2A9, and 
B136 in complex with the C1 domain of human FVIII. Details of these interactions could inform 
the development of future hemophilia A protein therapeutics with reduced immunogenicity. 
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Introduction 
 
Chapter 1 presents the physiological context of the research. First is presented a brief overview 
of blood coagulation and the role of blood coagulation factor VIII (FVIII) in the disease state of 
hemophilia A. Next, a brief history of blood coagulation research and a review of the biochemical 
process is described. Lastly, details of contemporary hemophilia A therapeutics are provided. This 
background information will be pertinent to the details discussed in Chapters 2, 3, and 4.  
Chapter 2 provides a brief introduction to the history and technique of X-ray crystallography 
and the subsequent computation of a three-dimensional molecular model. While the technical 
derivations of the molecular electron density map are omitted, this chapter undertakes a broad 
appreciation of the protein crystallographic method and how X-ray diffraction can be used to 
determine a molecular structure.  
Chapter 3 details the progress toward the recombinant isolated C1 domain of FVIII in complex 
with inhibitory antibodies. Work performed in the lab includes expression of the protein of interest 
from a bacterial expression system and chromatographic purification methods. Additionally, anti-
C1 antibodies were expressed and purified, and preliminary binding studies between the isolated 
C1 domain and anti-C1 antibodies were performed. 
Chapter 4 describes the solution of the molecular model of a novel human/porcine chimeric 
FVIII replacement protein “Et3i”, developed by collaborators at Emory University and Expression 
Therapeutics. This chapter encompasses the preparation of the crystal by previous researchers, 
treatment of the X-ray diffraction data set to generate an electron density map, and solution of the 
Et3i molecular model. Additionally, this has led to an improved model of human FVIII, refined 
against previously published 3.7 Å data. 
Citations of primary literature are denoted with numeral superscript. References to physical lab 
notebook entries are denoted by Roman numeral superscript and appended as footnotes to each 
respective page with the format (Researcher Initials(Notebook Number)Page Number).  
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Chapter 1: Blood Coagulation and FVIII 
1.1 Introduction to Blood Coagulation and Hemophilia 
In vertebrates, the circulatory system is a closed-system that plays a crucial role in the 
delivery of nutrients and removal of waste. In the event of vascular injury, a two-phase process 
termed “hemostasis” is initiated to preserve the vital blood supply. Immediately following damage, 
primary hemostasis initiates smooth muscle cell constriction to reduce blood flow to the wounded 
vessel. Next, platelets aggregate on the vessel walls near the site of injury to form a “soft-plug”. 
Secondary hemostasis involves activated thrombin’s proteolytic attack on fibrinogen to form fibrin, 
and the cross-linking of fibrin to form a clot across the vessel wound. This stable fibrin clot 
accompanies the transition of blood from a liquid to a firm gel state. Secondary hemostasis relies 
on a network of proteins, known as blood coagulation factors, which control unwanted clotting and 
localize coagulation to the site of injury. 
Hemophilia is an X-linked bleeding disorder in which hemostasis is interrupted because 
the gene for blood coagulation factor VIII (hemophilia A) or blood coagulation factor IX 
(hemophilia B) is inactive or damaged. The inability to stop bleeding from open wounds and 
crippling internal hemorrhaging are a few of the detrimental symptoms of hemophilia. The research 
of the Spiegel lab, and this document, will focus on blood coagulation factor VIII (FVIII) and 
hemophilia A. In hemophilia A, FVIII is either absent or non-functional, and the stable fibrin clot 
does not form effectively. There are degrees of severity for hemophilia A, depending on the amount 
of FVIII present. Severe hemophiliacs have <1% normal FVIII levels, moderate hemophiliacs have 
1%-5%, and mild hemophiliacs have >5% - <40% FVIII levels. 
1.2 Historical Overview of Blood Coagulation Research and Treatment 
The biochemical mechanisms underpinning blood coagulation were only recently 
understood, yet the phenomenon of uncontrolled bleeding that would come to be known as 
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hemophilia has a long history of investigation. In the second century A.D., Rabbi Judah in the 
Mishnah of Jewish law wrote that if a woman “circumcised her first child and he died [as a result 
of bleeding from the operation], and a second one also died [similarly], she must not circumcise 
her third child”.1 The medieval Islamic surgeon Albucasis wrote about bleeding disorders in his 
encyclopedic Al Tasrif, circa 1000 A.D.1,2 Queen Victoria of the United Kingdom was a hemophilia 
carrier, and many of her progeny bore the infamous “Royal Disease”. Her descendants included 
Prince Leopold who suffered an untimely death after a mild accident, and the severe hemophiliac 
Tsarevich Alexei Nikolaevich, whose compromising disease contributed to the downfall of the 
ruling house of Romanov in 1918 Imperial Russia.3 
One of the earliest clinical descriptions of hemophilia was by Dr. John Conrad Otto in 1803, 
who described “bleeders” and prescribed sodium sulfate to encourage hemostasis.4 Nasse first 
described a formula for the transmission of hemophilia in 18201,5, and it was in the Handbuch der 
Physiologie des Menchen (1833) that the German microscopist Johannes Müller described the 
protein “fibrin” as the constituent material of a blood clot.6 In 1840, Lane communicated the 
remarkable first therapeutic human blood transfusion to treat hemophilia (Figure 1).7  
Figure 1 Schematic of syringe used in first blood transfusion to treat hemophilia. The hemophiliac boy described by 
Lane suffered from a nearly mortal six-day bleed following an eye surgery. Prior to this, treatments for hemophiliac 
bleeding episodes were largely non-existent. (Lane, 1840)  
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In 1872, Schmidt noted that blood in contact with an open wound coagulated more readily 
than that collected by venipuncture. He theorized that fibrin must have a precursor, fibrinogen, in 
the blood and that a “zymoplastic” agent present in injured tissue must control the activation of 
prothrombin to thrombin and generation of stabilized clots.8 In the 1890s it was demonstrated that 
the addition of cation chelation agents such as citrate or oxalate could delay blood coagulation; 
indicating calcium ions were important for clotting.9–11 The first quantitative test for hemophilia 
was developed in 1893 by Wright, who placed blood into capillary glass tubes and inverted them 
at set time intervals until the blood had solidified.12 Following Hammarsten’s successful 
purification of fibrin in 1899,11,13 Morawitz’s 1905 “blood coagulation model” posited a tissue-
based “thrombokinase” protein (now known as Tissue Factor or “TF”) as the agent of prothrombin 
activation in the presence of calcium ions.14  
The twentieth century heralded the discovery of the blood coagulation factors, intermediary 
proteins that regulate blood coagulation from the initial exposure of extrinsic TF to the final 
formation of fibrin clots. In 1937, Patek and Taylor measured the effect of temperature on the 
coagulation time of citrated blood plasma, noting that at 48 °C an unknown clotting agent was 
completely inactivated. When this plasma was dialyzed against distilled water, they collected a 
protein precipitate which was separated from the plasma by centrifugation and re-suspended in a 
0.85% (w/v) sodium chloride solution. This 
precipitate resuspension retained the 
thermolabile clotting characteristic of whole 
plasma, and furthermore, could be used to clot 
samples of hemophiliac blood. This unknown 
“globulin substance” later became known as 
Anti-hemophilic Factor (AHF), or Factor VIII 
(FVIII) (Figure 2).15 
Figure 2 The thermolabile discovery of FVIII. Blood 
plasma held at 36 °C for 10 hours displayed decreased 
clotting capability. (Patek and Taylor, 1937)  
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The remaining blood coagulation factor discoveries came shortly, and include: Factor V 
(FV, a.k.a. Proaccelerin) by Owren in 194711,16; Factor XIII (FXIII, a.k.a. Laki Lorand Factor) by 
Laki and Lorand in 194817; Factor VII (FVII, a.k.a Proconvertin) by Koller et al. in 195118; Factor 
IX (FIX, a.k.a. Christmas Factor) by Biggs and MacFarlane in 195219; Factor XI (FXI, a.k.a. Plasma 
Thromboplastin Antecedent) by Rosenthal in 195320; Factor XII (FXII, a.k.a. Hageman factor) by 
Ratnoff and Colopy in 195521; and Factor X (FX, a.k.a. Stuart-Prower Factor) separately by Telfer 
and Graham in 1956 and 1957, respectively.22,23 The story of the discoveries of these blood factors 
is a fascinating one that unfortunately is outside of the scope of this document.  
The first descriptions of blood 
coagulation as a sequential cascade of protein 
interactions were independently published in 
1964, first by R. G. MacFarlane (Figure 3) and 
then shortly after by Davie and Ratnoff (Figure 
4).24,25 Initially conceived as a single 
“waterfall” route, the “blood coagulation 
cascade” came to describe the two “extrinsic” 
and “intrinsic” pathways, which both feed into 
the “common” pathway of thrombin-generated 
fibrin clot formation (Figure 5).26 The extrinsic 
pathway originates from exposed Tissue Factor 
(TF) protein on subendothelial cells external to 
the lumen of the vascular endothelium. The TF 
activates FVII (FVIIa), and TF:FVIIa in the 
presence of calcium activates FX (FXa). The 
intrinsic pathway relies on activated FXII (FXIIa) generating activated FXI (FXIa), which in turn 
activates FIX (FIXa). Separately, thrombin cleaves FVIII in complex with the carrier protein von 
Figure 3 Enzyme Cascade Model of Blood Coagulation. 
(MacFarlane, 1964) 
Figure 4 The Waterfall Model of Blood Coagulation. 
(Davie and Ratnoff, 1964)  
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Willebrand’s Factor (vWF) to activate FVIII (FVIIIa) and dissociate it from vWF. The coordination 
of FVIIIa and FIXa is known as the intrinsic FX-ase (or “Ten-ase”) complex. The common pathway 
is composed of the FXa:FVa complex that 
cleaves prothrombin (FII) to thrombin (FIIa). 
Thrombin in turn cleaves fibrinogen (FI) into a 
mesh of fibrin (FIa), which is cross-linked by 
FXIIIa to form stable fibrin clots. 
In 2001, Hoffman proposed a novel 
cell-based model for hemostasis. In contrast to 
the blood coagulation cascade’s focus on 
protein factors, the cell-based model describes 
three-phases (initiation, propagation, and 
amplification) wherein hemostasis is controlled 
by the presence and activation of specific 
cellular features (Figure 6). In the Initiation 
phase, extravascular TF-presenting cells (e.g., 
fibroblast cells) serve as the origin of activation 
for FVIIa, FXa, thrombin, and FIXa. However, 
FXa is quickly degraded by anti-coagulation 
proteases if it leaves the extravascular cell 
surface. The Amplification phase consists of the 
trace thrombin generated during initiation 
traveling to nearby platelet surfaces and 
activating platelet surfaces, FV, FVIII, and FXI. 
Once the platelets and factors have been primed, the Propagation phase produces a concentrated 
burst of activated thrombin to produce fibrin clots. This model addresses issues raised by the 
Figure 6 The Cell Based Model of Hemostasis. The 
presence of anti-coagulation proteases localizes FXa to 
cellular surfaces. Thrombin generated at TF-presenting 
extravascular cells during “Initiation” travel to platelet 
surfaces to “Amplify” platelet and factor activation and 
allow high-output “Propagation” of thrombin activation. 
(Hoffman, 2001) 
Figure 5 The Blood Coagulation Cascade. The extrinsic 
and intrinsic routes funnel into the “common” pathway of 
thrombin activation by FXa:FVa in the presence of Ca2+. 
Factor I (FI) is omitted from this diagram. 
(Spiegel and Stoddard, 2002)  
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historical cascade model in explaining hemostasis in vivo, such as why extrinsic FVIIa/TF-initiated 
FXa cannot compensate for missing FVIII or FIX activity in hemophiliacs.27 
While whole blood transfusions represented the first form of treatment for hemophilia, the 
standard of care until the 1960s was frozen or lyophilized plasma in response to a bleeding episode. 
One complication of plasma therapy was that whole plasma delivered the entire protein profile and 
~50% of the volume of blood instead of only the necessary clotting factors. Hypervolemia 
(excessive blood fluid) and organ failure were often the limiting factors for the rate and efficacy of 
plasma infusion used to treat bleeding episodes. In 1964, Dr. Judith Graham Pool communicated a 
procedure of quickly thawing frozen plasma and collecting the precipitation of blood coagulation 
factors which formed.28–30 This concentrated “cryoprecipitate” ushered in a marked improvement 
in patient care, as it granted the ability to deliver small therapeutic dosages and prophylactic 
treatment of hemophilia with regular infusions.31 Unfortunately, approximately 30% of patients 
receiving FVIII-containing whole blood, plasma, or concentrates develop anti-FVIII inhibitory 
antibodies (Figure 7). These “inhibitors” reduce the efficacy of replacement factor treatment and 
increase the severity of hemophilia symptoms. Hemophiliacs with absent or significant deletions 
of FVIII have 20-80% risk of developing an inhibitor, whereas those with minor missense 
mutations demonstrate an inhibitor prevalence 
of 5%.32 Furthermore, researchers have 
identified stereotypes of patient immune 
response to FVIII, including “high-responders” 
and “low-responders”. High-responder patients 
maintain elevated immunogenic memory, 
increase the affinity of antibodies to FVIII with 
exposure, and have high-titer antibodies. Low-
responder patients, on the other hand, do not 
exhibit these immunity changes (Figure 7).33  
Figure 7 "Low-responder" Patient Antibody Titer. This 
patient displayed sustained titer level with normal FVIII 
dosages. (Allain and Frommel, 1976)  
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 In the early 1900s, the main treatment for inhibitory antibodies was general 
immunosuppression therapy with cytotoxic nitrogen mustard compounds. First discovered by WWI 
physicians who noted decreased white blood cells in soldiers exposed to mustard gas, therapeutic 
alkylating agents such as cyclophosphamide relied upon the formation of cyclic ammonium to 
covalently bind to DNA guanine nucleobases and induce cell apoptosis (Figure 8, Figure 9). While 
devastating to cell populations engaged in the immune response, the many off-targets affected by 
this therapy were not ideal.34  
In 1977, Brackmann and Gormsen 
reported immune tolerance induction (ITI) as an 
alternative to general immunosuppression in the 
treatment of inhibitory antibodies. The patient 
was delivered large doses (>1000 U/day) of FVIII 
for several months; after an initial strong immune 
response, their FVIII inhibitor titer reduced (Figure 10).35 The mechanism by which ITI proceeds 
is not fully understood, but proposals include clonal deletion of anti-FVIII B cells, receptor editing 
of antibodies, regulatory T cell induction, and anti-idiotypic antibodies.36 The success of ITI 
campaigns has been shown to depend on the patient age, the FVIII inhibitor titer, and the dose of 
replacement FVIII.36 Data from the International Immune Tolerance Registry (IITR) indicated that 
higher dosages of FVIII (>200 IU/kg/day) in ITI protocols correlate to increased success rates.36  
These advances in treatment were soon the fulcrum for an epidemic that particularly 
devastated the hemophilia community, as the 1980’s marked the outbreak of the human 
immunodeficiency virus (HIV). On June 5th, 1981, the Centers for Disease Control (CDC) 
Figure 9 Cyclophosphamide Pathway of Activation. 
Modification of the mustard nitrogen’s nucleophilicity 
allows for therapeutic pro-drug administration that 
requires activation in the liver. (Hall and Tilby, 1992)  
Figure 8 Sulfur Mustard Mechanism of Action. The highly 
reactive cyclic intermediate disrupts DNA and many off-
targets. (Hall and Tilby, 1992) 
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Morbidity and Mortality Weekly Report 
(MMWR) communicated that five immune-
compromised men in Los Angeles were 
diagnosed with Pneumocystis carinii 
pneumonia (PCP). This peculiar infection by 
an opportunistic fungus would come to be 
recognized as a symptom of Acquired Immune 
Deficiency Syndrome (AIDS). Not long after 
this, on July 16th, 1982 the CDC communicated 
hemophiliacs who had received blood factor 
concentrates had developed AIDS.37,38 While 
HIV was suspected in the blood supply as early as 1982, due to lack of knowledge about HIV and 
resistance from the Food and Drug Administration (FDA) it was not until late 1984 that steps were 
taken to deactivate the virus in the blood supply through heat-treatment.39 By 1993, a class action 
lawsuit against the National Hemophilia Foundation and blood-derived therapeutic companies 
claimed approximately 10,000 hemophiliacs had contracted HIV from the contaminated blood 
supply.40 
1.3 FVIII Molecular Details 
The FVIII protein is expressed from the 187 kilobase F8 gene, comprised of 26 exons and 
~9 kilobase pairs of coding sequence. First described by Gitschier in 1984, at the time of 
communication, F8 was the largest gene yet characterized, encompassing ~0.1% of the human X 
chromosome (Figure 11).41 The gene contains three sequential “A” domains, a unique “B” domain, 
and two sequential “C” domains.  
Figure 10 Immune Tolerance Induction (ITI) Campaign in 
a "High-responder" Patient. The FVIII inhibitor U/mL is 
reported in Bethesda dilution factor of antibodies present. At 
1200U/mL the patient’s blood could be diluted 1200 X and 
still clear 50% of the FVIII present in a normal blood 
sample. (Brackmann and Gormsen, 1977)  
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The A domains have a 30% homology pairwise (20% conserved among all three) and are related 
to the copper-binding protein ceruloplasmin, while the C domains share a 37% homology and are 
related to the membrane-binding discoidin protein family.41 The 2332 amino acid residue FVIII 
protein is expressed with the domain sequence of A1-A2-B-A3-C1-C2.  Consideration of the non-
overlapping C1 and C2 domain intron boundaries in the gene led researchers to postulate that the 
domains are the results of a DNA segmental replication event. Conversely, the B domain may stem 
from a processed gene insertion into the established A2-A3 boundary area.41  
A second transcript of the F8 gene has been identified, a reverse direction ~1700 base copy 
originating in a CpG island within intron 22. This transcript was demonstrated to express in a wide 
variety of cell types.42 Additionally, a third transcript of the F8 intron 22 region has been identified; 
an in-frame, eight amino acid sequence which is spliced to exons 23-26 containing the  C2 domain 
of FVIII.43 Approximately 40% of the genetic mutations resulting in severe hemophilia A are the 
intron 22 inversion (I22I) of the F8 gene. This mutation interrupts the secretion of FVIII, and 
patients with this mutation have no endogenously synthesized FVIII circulating in their blood.43–45  
The synthesis of FVIII occurs in hematopoietic Kupffer cells, somatic liver sinusoidal 
endothelial cells, and extrahepatic endothelial cells.46 FVIII does not express at high levels 
endogenously, with average serum concentrations of 0.5 nM.47 To be secreted from the cell, FVIII 
must be proteolytically cleaved intracellularly at residue R740 and R1689 by Furin (a.k.a paired 
basic amino acid cleaving enzyme (PACE)), which partially removes the FVIII B domain. This 
processed heterodimeric FVIII contains a domain sequence of A1-A2/A3-C1-C2. In the absence of 
a hemostatic event, the carrier glycoprotein von Willebrand’s Factor (vWF) complexes to inactive 
Figure 11 Map of the F8 Gene. The gene contains 26 exons and contains the protein domain sequence A1-A2-B-A3-
C1-C2. The B domain is subsequently excised in wildtype FVIII maturation, and is often omitted from recombinant 
FVIII constructs (denoted as B-Domain Deleted a.k.a. BDD). (Gitschier et al., 1984)  
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FVIII and shields it from proteolysis and some clearance receptors in the blood. The binding 
interaction between FVIII and vWF is not fully understood, but interactions have been 
demonstrated between FVIII and the D’ domain of vWF.48–50 Intracellular complexes of vWF:FVIII 
have been shown to be secreted from cells in Weibel-Palade bodies.51 
In the event of vascular injury, vWF binds to activated platelet surfaces expressing the 
glycoprotein Ib-IX (GpIb/IX) receptor, bringing the vWF:FVIII complex in proximity to the site 
of coagulation. Inactive, heterodimeric FVIII is then cleaved by thrombin (FIIa) at residue R372 to 
dissociate from vWF and become an activated FVIII heterotrimer (FVIIIa) with the domain 
structure A1/A2/A3-C1-C2. The C1 and C2 domains of FVIIIa bind to phosphatidylserine (PS) 
rich activated-platelet surfaces, where FVIIIa and FIXa associate to form the intrinsic “Ten-ase” 
Complex, and enzymatically cleave FX to form FXa.27,50,52 FVIIIa is inherently unstable in the 
heterotrimeric form, and the A2 domain spontaneously dissociates from the core protein. Once the 
A2 domain has detached, the half-life of FVIIIa is significantly decreased.53 
Both free FVIIIa and FVIII:vWF are regularly recycled from the blood. While clearance 
receptors for FVIIIa, vWF, and for vWF:FVIII are not fully understood, the identified receptors 
include: low-density lipoprotein receptor (LDLR); low-density lipoprotein receptor-related protein-
1 (LRP1); asialoglycoprotein receptor (ASGPR); macrophage mannose receptor type 1 
(MMR/CD206); heparan sulfate proteoglycans; sialic acid binding IgG-like lectin 5 (Siglec5); 
scavenger receptor class A member 5 (SCARA5); stabilin-2 (STAB2); and C-type lectin domain 
family 4 member M (CLEC4M).46,54 
The presence of terminal sialic acids on vWF glycan sites positively contribute to the levels 
of serum vWF present. In 2015, Yang presented a model of protein degradation based upon 
exposure to glycosidases and asialylated protein recognition by lectin-like-receptors (LLR).55 
Knockout of an LLR “MGL”, which presents the receptor for hyposialyated vWF, significantly 
extends the serum half-life of vWF. Future research is investigating the role of FVIII sialyation and 
clearance.55–57 
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Recent work has highlighted the Ashwell Morell receptor (AMR) in vWF clearance.  
Predominantly expressed on the surface of hepatocyte cells, AMR is an (ASGPR), and the first 
recognized C-type (requiring calcium) lectin (glycan-binding protein), originally demonstrated in 
binding asialylated ceruloplasmin. Human ASGPR proteins also capture and signal the destruction 
of glycan proteins with terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues not 
produced endogenously in humans. Glycan mediated immunogenicity represents an considerable 
challenge for replacement FVIII:vWF products produced in non-human mammalian cells.54 
1.4 Modern Hemophilia A Therapies 
Recombinant FVIII was first produced by Wood et al. at Genentech in 1984, approved 
under the brand name Recombinate™ in 1992. Today, a number of recombinant products form the 
gold standard for hemophilia A therapy.58 In addition to unmodified FVIII, classes of therapeutics 
include but are not limited to small molecule therapies, modified FVIII constructs, bypassing agents 
for use in the presence of an inhibitor, and developments towards gene therapy. Highlights of 
current or communicated future therapeutics include:  
 
SMALL MOLECULE THERAPIES 
These low molecular weight pharmaceutical compounds are used to effect a physiological change 
in a hemophilia patient, without directly providing replacement blood coagulation factor. 
 
Desmopressin acetate (1-deamino-8-D-arginine vasopressin, DDAVP // Ferring Pharmaceuticals) 
(FDA approved, patent expired) 
A synthetic analog of the hormone vasopressin, Desmopressin stimulates the secretion of 
vWF release from endothelial cells. The increased concentration of vWF favors formation of the 
protective vWF:FVIII complex and reduces proteolytic degradation of free FVIII. This treatment 
is only for those with mild FVIII deficiency.59 
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Epsilon-aminocaproic Acid (Amicar // Akorn, Inc.) 
(FDA approved) 
Epsilon-aminocaproic Acid (EACA) is an inhibitor of the plasminogen-mediated “fibrinolytic” 
pathway for degradation of formed fibrin clots. While EACA administered alone will not 
compensate for a severe hemophiliac’s complete inability to form fibrin clots, it has found use as 
an adjunct therapy to support clotting during dental procedures and minor surgery.60 
 
MODIFIED REPLACEMENT FVIII 
These therapeutics augment the architecture and functionality of FVIII to increase half-life, 
stability, and efficacy of replacement therapy.  
 
Anti-vWF-Nanobody FVIII Fusion Protein (FVIII-KB013bv // Novo Nordisk A/S)  
(Under Development) 
Heterodimeric FVIII dissociation from vWF is strongly correlated with increased FVIII 
clearance from the blood by proteolysis and the immune system. Generating a FVIII therapeutic 
with an increased affinity for vWF would strengthen the vWF:FVIII complex and reduce the 
immunogenicity of the replacement FVIII therapy. Lenting et al. communicated a recombinant 
FVIII construct with the B domain replaced by an anti-vWF camelid single domain antibody 
(nanobody). This FVIII-nanobody fusion protein, “FVIII-KB013bv”, demonstrated a 100-fold 
reduction in KD from vWF, and a two-fold half-life increase in vivo compared to recombinant FVIII 
(rFVIII).61 
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Human/Porcine Chimeric FVIII (Et3i // Expression Therapeutics) 
(Under Development) 
Due to the large quantity of FVIII required for ITI campaigns, development of a high-yield 
recombinant human FVIII (rhFVIII) is of high interest to the hematological community. 
Recombinant B-domain-deleted (BDD) porcine FVIII (rpFVIII) expresses at 10-14 fold higher 
levels than rhFVIII.62 A novel human/porcine chimeric construct (“Et3i”) containing the porcine 
A1 and A3 domains expresses 5.3 ± 0.75 fold higher than rhFVIII from transiently transfected 
COS-7 cells and stably transfected BHK cells, while maintaining comparable clotting activity.63 
Et3i has recently received positive feedback from an FDA Pre-Investigational New Drug (IND) 
program. Additionally, Et3i is being evaluated as a potential gene therapy candidate, as transgenic 
Et3i transfected BHK-M cells demonstrated ~13 fold greater expression than BDDhFVIII.63–65 
 
Site-directed PEGylated rhFVIII (BAY 94-9027 // Bayer) 
(FDA Investigational Agent Biologics License Application (BLA) accepted)  
Commonly, polyethylene glycol (PEG)-FVIII products rely on N-hydroxy succinimide 
(NHS) ester chemistry for PEGylation, an effective though inaccurate conjugation targeting lysine 
or N-terminal amine residues. BAY 94-9027 is a site-directed PEGylated FVIII using engineered 
cysteine and maleimide chemistry. Several sites were screened for cysteine insertion, and 
optimization of PEGylation increased BAY 94-9027 half-life sufficiently to allow prophylaxis once 
every seven days.66,67 
 
B-Domain Selectively PEGylated rhFVIII (Adynovate, BAX855 // Shire Pharmaceuticals) 
(FDA Approved) 
Adynovate is a modified recombinant human FVIII (rhFVIII) construct with ~60% of the 
PEGylation selectively targeted to the B domain. This reduces unwanted PEGylation at sites that 
would cause steric hindrance of FVIII binding to vWF, phosphatidylserine (PS) platelet membrane 
15 
 
surfaces, or coordinating FIXa and FX. Additionally, the majority of the B domain is enzymatically 
removed from FVIII during thrombin activation to the heterotrimeric form. Adynovate 
demonstrated 1.4-1.5 fold increased half-life (T1/2) and residence time compared to unmodified 
recombinant human FVIII.68 
 
Antibody Crystallizable Fragment (Fc) rhFVIII Fusion Protein (Eloctate // Bioverativ Inc.) 
(FDA approved) 
The neonatal Fc receptor (FcRn) is an MHC class I-like protein which recognizes the Fc 
region of IgG1 antibodies. In vascular endothelial cells, endosome-expressed FcRn rescues and 
recycles pinocytosed antibodies from the lysosomal degradation pathway.69 A B-domain deleted 
(BDD) FVIII-(IgG1 Fc domain) fusion protein has been created (rFVIII-Fc) to take advantage of 
this FcRn functionality. The rFVIII-Fc construct does not reduce clearance of vWF:FVIII 
complexes by liver hematopoietic Kupffer cells, but has demonstrated recycling of uncomplexed, 
free-rFVIII-Fc by somatic liver sinusoidal cells. In clinical phase 1/2a and 3 (A-LONG) trials, the 
rFVIII-Fc construct demonstrated ~1.5 fold increased half-life compared to rFVIII.46,70  
 
A2-A3 Disulfide Anchored FVIII (Bayer) 
(Under development) 
The spontaneous dissociation of the heterotrimeric FVIIIa A2 domain hinders the potential 
half-life of replacement therapies. Gale et al. communicated a rFVIII that contains an engineered 
cysteine pair (C664-C1826) disulfide bridge between the A2 (heavy chain) and A3 (light chain) 
domains of heterotrimeric FVIII. This construct has demonstrated increased half-life in vivo while 
maintaining binding affinity for vWF and normal proteolytic degradation by activated protein C 
(APC).53,71 
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Porcine FVIII (Obizur, OBI-1// Shire Pharmaceuticals) 
(FDA approved) 
Following the communication of the cDNA for the porcine FVIII gene,72 the use of porcine FVIII 
has been demonstrated as an effective alternative therapy in hemophilia A patients with anti-FVIII 
inhibitors.73 Obizur is a B-domain deleted (BDD) porcine FVIII therapeutic that has low 
immunogenicity in patients with established anti-hFVIII titers.74 
 
BYPASSING AGENTS 
For patients with potent inhibitors, even radically modified rFVIII at high dosages can be 
ineffective. Bypassing agent therapeutics do not rely on modifications to FVIII. Instead, they 
circumvent the function of FVIIIa by enhancing alternate routes through the coagulation cascade 
to augment clotting capability. These therapies are most likely used in conjunction with ITI 
campaigns.  
 
Anti-FIX-FX Bispecific Antibody (Hemlibra, Emicizumab, ACE910 // Roche) 
(FDA approved with black box warning) 
Hemlibra is a prophylactic bispecific humanized antibody that binds FIXa and FX, 
replacing FVIIIa’s coordinating role in the Ten-ase complex. Due to neonatal Fc receptor (FcRn) 
recycling, Hemlibra demonstrates significantly improved half-life of 4-5 weeks compared to 
traditional prophylaxis treatment. In clinical trials, minimal anti-Hemlibra antibodies were 
detected, although recent thrombosis (clot-formation) complications have caused the FDA to issue 
a warning.75,76 
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Activated FVII bypassing agent (NovoSeven, rFVIIa // Novo Nordisk A/S) 
(FDA approved) 
Recombinant activated FVII (rFVIIa) has been shown effective as a backup regimen for 
hemophilia A patients with inhibitors. Termed “secondary prophylaxis”, rFVIIa generates 
increased amounts of extrinsic pathway TF:rFVIIa activated FX to maintain clotting capability and 
avoid bleeding induced arthropathy during high inhibitor loads.77 
 
Activated prothrombin complex concentrate (FEIBA NF - Shire) 
(FDA approved, patent expired) 
To overcome inhibitors, the therapeutic Factor Eight Inhibitor Bypassing Activity (FEIBA) 
provides a cocktail of factors II, IX, X and VIIa to overcome the deficient FVIIIa.78 
 
 Anti-Tissue Factor Pathway Inhibitor Antibody (Concizumab // Novo Nordisk A/S) 
(Phase 1 Clinical Trials) 
The Tissue Factor Pathway Inhibitor (TFPI) protein reversibly inhibits the formation of 
FVIIa/TF-initiated FXa. Concizumab is a humanized monoclonal anti-TFPI antibody which allows 
increased levels of extrinsic FVIIa/TF-generated FXa to accumulate and compensate for the lack 
of intrinsic FVIIIa/FIXa functionality.79  
 
GENE THERAPY 
Gene therapy is an attempt to correct defective or absent genetic information in the cells of 
a diseased organism. While still in the developmental stages for humans, animal models of 
Hemophilia A with retroviral/lentiviral, adenoviral, and adeno-associated viral (AAV) have been 
successful. 
The challenges presented by viral transduction of a therapeutic gene are numerous. For 
example, first-generation retroviruses cannot penetrate the nuclear membrane, and can only 
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transduce dividing cells. Lentiviral vectors can infect non-dividing cells, but expression of a foreign 
protein on infected antigen presenting cells (APCs) can trigger immune deletion of the altered cells. 
Additionally, the risk for oncogenesis when using viral therapies is a dire concern. Despite these 
complications, gene therapy has the potential to cure hemophilia and is the subject of intense 
research.80 
 
Platelet-localized FVIII (Blood Research Institute, Blood Center of Wisconsin) 
(Under Development) 
 Lentiviral transduction of FVIII into hematopoietic stem cells (HSC’s) generated platelets 
containing FVIII protein and mRNA. Due to activated platelets localization to the site of vascular 
injury, therapeutic recovery of hemostasis can be achieved using this method with levels of FVIII 
much lower than in replacement therapy.81  
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Chapter 2: Protein X-Ray Crystallography and Molecular Modeling 
2.1 A Brief History of Protein X-ray Crystallography 
During the winter of 1611 in Prague, Johannes Kepler published the booklet A New Year’s 
Gift, or on the six-cornered Snowflake for his patron Counselor John Matthew Wacker. In it, Kepler 
pondered the six-sided snowflakes falling outside, and surmised that their hexagonal shape “could 
not be a property of the water vapor, which lacks form, or of the cold air; but must have been a 
particularly suitable or favorable orientation for the water to arrange in”.82 This was the first 
published work attempting to establish a connection between the 
outer appearance of a material and the internal organization of its 
regular-packing components (Figure 12). Kepler drew 
comparisons between snowflakes and the hexagonal arrangement 
of honeycombs or the rhombohedral surfaces of a pomegranate 
seed, but he was unable to answer his inquiry, stating “...I have 
knocked at the door of chemistry and see how much remains to be 
said before we can get hold of our cause…”.82  
This question would go unanswered for nearly three 
centuries, until 1895 when the German physicist Wilhelm 
Röntgen demonstrated the existence of X-rays and the 
capability to probe the interior of a solid (Figure 13). He 
received the first Nobel prize in Physics in 1901 for his 
discovery; although he never fully revealed the details of his 
experimentation, and due to his reclusive nature even avoided 
giving his Nobel lecture.83 In 1912, Max von Laue reported 
using crystals of copper sulfate as a “diffraction grating” for X-
rays, demonstrating both the wave-like nature of X-rays and the 
Figure 12 Comparison between 
cubic (A) and rhomboid (B) packing 
of spheres. (Kepler, 1611)  
Figure 13 First communicated X-ray 
image. (Röntgen 1896. Rosenow 1995)  
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regularity of crystal lattices, earning him the 1914 Nobel Prize in Physics.84,85 Sirs William and 
Lawrence Bragg related the production of X-ray reflections to the distance between crystal lattice 
planes, formalized in Bragg’s law, earning Lawrence the 1915 Nobel Prize in Physics.86  
Later, as the Cavendish Professor of Physics at Cambridge, Sir Lawrence Bragg 
encouraged his protégés Max Perutz and John Kendrew towards the structural determination of 
hemoglobin and myoglobin. Beginning in 1937, Perutz spent twenty-two years attempting to solve 
the molecular structure of hemoglobin. He made little headway until 1953 when he soaked protein 
crystals of hemoglobin in mercury to bind to 
cysteine residues. This isomorphous 
replacement with heavy metal atoms allowed 
Perutz to calculate the phase angles of the X-
rays diffracted from protein crystals, the aptly 
named “phase problem” of crystallography. 
Kendrew published the three-dimensional 
structure of myoglobin in 195887, shortly 
followed by Perutz with the structure of 
hemoglobin in 196088; feats for which they 
jointly received the 1962 Nobel Prize in 
Chemistry. 
There are two principal modern light sources used to generate X-rays for protein crystal 
diffraction, the X-ray diffractometer, and the synchrotron particle accelerator. In an X-ray 
diffractometer, a vacuum-sealed cathode filament emits electrons to an anode (typically copper 
(Cu) for protein crystallography). Excitation and relaxation of the anode Cu electrons generate a 
broad spectrum of X-rays, but predictable peaks of radiation are emitted when incoming cathode-
generated electrons eject resident Cu electrons from the innermost (K) shell. Cu electrons from 
Figure 14 Structural Model of Hemoglobin. At the time of 
publication, the structural basis for hemoglobin’s dynamic 
oxygen affinity remained a mystery. This structure revealed 
a distant placement of heme groups between protein 
subunits, implicating a quaternary protein structure basis 
for allostery. (Perutz, 1960) 
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outer (L or M) shells then relax into these vacant (K) positions and emit peaks of X-rays at specific 
wavelengths, producing the Kα (K-L) or Kβ (K-M) emission wavelengths.85  
Synchrotron X-ray radiation, by comparison, takes advantage of the fact that electrons or 
positrons experiencing acceleration emit X-rays. Furthermore, there is a correlation between the 
intensity of particle acceleration, and the wavelength of X-rays emitted. Unlike a diffractometer, 
where the peak wavelength distribution of X-rays generated is dependent on the anode element 
(Cu), synchrotron particle accelerators employ complicated “wiggler” or “undulator” paths which 
particles must pass through. Synchrotrons generate high-brilliance and tunable wavelength X-ray 
radiation for use in crystallographic experiments.85 
2.2 Protein Crystallography 
A simplified model of protein 
crystallization occurs in two phases, 
nucleation, and growth. A saturated solution of 
protein is perturbed, either through chemical 
additives, osmosis, or evaporation to become 
supersaturated (Figure 15). The highly 
concentrated solution seeks to regain equilibrium and will precipitate proteins from the solution to 
a solid phase. If this transition is approached correctly, the precipitated protein forms an ordered 
aggregate nucleus and then recruits free-solution molecules. A common method for achieving 
supersaturation and protein crystallization is hanging drop 
vapor diffusion; wherein a droplet of protein solution is placed 
in a hermetically sealed vapor equilibrium with a “mother 
liquor” of higher osmotic strength.89 (Figure 16) 
Before exposure to X-rays, protein crystals are 
commonly “cryo-protected” (for example with dimethyl 
Figure 16 Hanging Vapor Drop 
Diffusion.(Hampton Research) 
Figure 15 Protein Crystallization Solubility Curve. The 
supersaturated protein solution initiates the nucleation of 
the crystal followed by slow growth. (Rhodes, 2006)  
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sulfoxide (DMSO) or glycerol) and then flash-frozen in liquid nitrogen. This treatment allows water 
in the crystal and droplet to vitrify, forming non-crystalline amorphous ice, and lower temperatures 
reduce diffusion of oxygen radicals formed from X-ray radiation within the protein crystal.85,89 
Protein crystals can be modeled as a lattice of repeating blocks, the smallest of which 
contains all the structural information of the crystal. These blocks, known as the asymmetric units, 
are related to their neighbors by crystallographic symmetry and are therefore identical. However, 
each asymmetric unit can contain multiple molecules which do not have crystallographic symmetry 
and can adopt different conformations.85 
The asymmetric unit combined with symmetry operators creates the next largest 
component within the crystal, the unit cell. The unit cells of a crystal can be defined as having 
vectors a, b, and c, and angles α, β, and γ (Figure 17). The crystallographic symmetry operators (n-
fold symmetry, screw axis, mirror plane, glide plane, inversion center) can be combined into 230 
configurations, or space groups. However, the 
chiral nature of L-amino acids limits the possible 
space groups for proteins to 65.90 These unit cells 
are the smallest volume of space that contains all 
the structural and symmetry information of the 
crystal, and that repeated by translation will 
create the entire crystal in three dimensions.  
2.3 X-ray Diffraction 
X-rays are electromagnetic waves which travel as a cosine function, with energy 
𝐸(𝑡 = 0; 𝑧) = 𝐴𝑐𝑜𝑠2𝜋 (
𝑧
𝜆
), where A is equal to amplitude, z is equal to distance traveled, and λ 
stands for wave period. X-ray waves incident on a molecular electron system are absorbed by the 
electrons, which then emit X-ray waves of the same frequency. 
Figure 17 The Unit Cell and the reflecting planes. 
Incident X-rays along S reflect against imaginary planes 
within the crystal lattice. (Drenth, 1999)  
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X-rays are scattered almost exclusively by the electrons in a crystal. The angles in which 
X-rays are diffracted by a protein crystal hold information about the dimensions of the unit cell. 
Additionally, the intensities of the diffracted X-rays reveal details about the distribution and 
identity of the electron density of the crystal structure.  
Diffraction of X-rays can be modeled as reflections against imaginary “reflecting planes” 
within the crystal lattice; planes that are parallel, equidistant with perpendicular distance = d, and 
with plane boundaries defined as integer indices (h,k,l) dividing the unit cell a,b,c axes (a/h, b/k, 
c/l) (Figure 17).85,91 When the distance between these reflecting planes results in complete 
constructive interference, X-ray diffraction is measurable and described by Braggs Law: 2𝑑𝑠𝑖𝑛𝜃 =
𝜆. Where d equal to the reflecting plane distance, and θ is equal to the angle between the incident 
X-ray and the lattice plane. The crystal resolution is described by this Bragg distance (d); with a 
crystal of 5 Å being poor quality, 2.0-2.5 Å normal quality, and 1.0-1.5 Å high quality (Figure 
18).85,90,91  
Consider beams striking electrons (e1 and e2) in a lattice, spaced by distance r (Figure 19). 
The diffracted beam from e2 travels a path that is 𝑝 + 𝑞 longer than the diffracted wave by e1, 
resulting in a phase difference (“Z”) between the waves unless 𝑝 + 𝑞 is equal to an integer of 2𝜋𝜆.  
Figure 18 Scattering against a crystal lattice plane. X-rays (arrows) incident from angle θ to a 
crystal lattice plane will appear to reflect away at angle 2θ. (Blundell and Johnson, 1976)  
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Waves of the same wavelength and 
amplitude but separated by a phase shift of Z, 
(
𝑍
𝜆
) × 2𝜋 = 𝛼, can be summed together 
(Figure 20). The waves can be directly 
compared by breaking both waves into real and 
imaginary parts, at phase shifts of 0 and 90° 
respectively. Where wave 1 is the real wave 
components, and wave 2 is the imaginary wave 
components. These can be graphically related 
with an Argand diagram (Figure 21).  
The summation of waves allows the scattering of an entire atom can be summed, and results 
in the atomic scattering factor “f”. Furthermore, the scattering of all the atoms in the unit cell can 
be summed and produces the structure factor “F(S)”. Finally, the scattering from all unit cells in 
the crystal can be aggregated into the crystal scattering factor K(S).85 
 
Figure 19 X-ray scattering by system of two electrons. 
Incident X-rays along So that diffract off e2 towards S will 
travel a distance of p+q farther than X-rays diffracting off 
e1. (Drenth, 1999) 
Figure 20 Comparing two waves offset by phase. 
An original wave can be summed with a new wave, 
offset by phase angle Z. The resulting wave sum will 
exhibit either constructive or destructive interference. 
(Drenth, 1999)  
Figure 21 The Argand Diagram. The real and imaginary 
components of a wave can be graphed along orthogonal 
axes. The total wave A is depicted as a dot product vector 
with real (Acosα) and imaginary (Asinα) components, 
with angle α equal to the phase angle. (Drenth, 1999)  
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2.4 Phase Determination, Model Building, and Refinement 
For the structure building discussed in this document, phase angles for the X-ray 
diffractions were solved by molecular replacement (MR).  
The MR computational method for calculating the phase angles utilizes previously 
published molecular structures as templates and maximizes “model fit” solutions to the calculated 
electron density map. First, a published molecular structure is superimposed into electron density 
and then rotated and translated through the unit cell until an approximate electron density fit and 
estimated phase angle calculation is found. 
Once a model is generated, a molecular 
graphics program for model building and 
refinement, such as WinCoot can be used to 
manually manipulate the model’s atomic 
coordinates (Figure 22).92,93 In tandem to 
manual adjustments of the model, automated 
refinement of the molecular structure and 
electron density map can be accomplished 
through software suites such as Phenix (Figure 
23).94 
Several metrics monitor how well a molecular model fits into the crystal electron density. 
The constructed model is used to generated a calculated electron density map, and the agreement 
between the observed and calculated structure factors (Fo and Fc) is described by the R factors, Rwork 
and Rfree, where  
𝑅 =
Σ𝑎𝑙𝑙 𝑟𝑒𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛𝑠 |𝐹𝑜−𝐹𝑐|
Σ𝑎𝑙𝑙 𝑟𝑒𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛𝑠|𝐹𝑜|
.  
Figure 22 WinCoot Model Building. Individual amino 
acids (red) are manipulated to optimize placement within 
the calculated electron density map (blue wire mesh).  
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The Rwork term describes the total agreement between the molecular structure and the 
electron density. Additionally, the Rfree term describes the correlation of the model against ~10% 
of the reflections that are reserved from any refinement and is a measure of how biased the electron 
density has become as a result of refinement. Additional structural information such as bond 
lengths, angles, and Ramachandran outliers are used to determine the geometric feasibility of the 
molecular structure.95 
 
  
Figure 23 Automated model refinement with Phenix. Standard metrics of model accuracy (Rwork, Rfree) provide 
quantitative, real-time tracking of changes made during computational refinement cycles. 
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Chapter 3: Isolated C1 Domain of FVIII in Complex wit Inhibitory Antibodies 
3.1 Introduction 
A major complication of hemophilia A treatment with replacement FVIII is the development of 
inhibitory antibodies. Previous work in the Spiegel lab identified the atomic binding interactions 
between the C2 domain of FVIII and the anti-C2 inhibitory antibodies 3E6 and G99. The epitope 
bound by 3E6 included the C2 Arg2209-Ser2216 sequence, while G99’s epitope on the opposing face 
of C2 comprised the Pro2221-Trp2229 sequence.96,97 This investigation not only illuminated the 
interaction between C2 and inhibitory antibodies, but it also augmented the understanding of how 
C2 binds to phosphatidylserine (PS) rich activated-platelet surfaces.98 
While the C2 and A2 domains of FVIII have long been considered the most immunogenic 
domains, a substantial number of anti-C1 domain antibodies have been identified.99 The C1 domain 
of FVIII has been shown to play a pivotal role in PS platelet membrane binding, vWF binding, and 
uptake by dendritic cells.99 Two distinct anti-C1 epitopes recognized by anti-C1 antibodies were 
determined by competitive enzyme-linked immunosorbent assay (ELISA) and hydrogen deuterium 
exchange mass spectroscopy (HDX-MS).96,100 Seven “Group A” epitope antibodies displayed high 
affinity for FVIII but weakly interrupted FVIII binding to PS surfaces, vWF or procoagulant 
activity. A singular “Group B” antibody, strongly inhibited FVII’s binding to vWF, procoagulant 
activity, and binding to phospholipid membranes.99,101 This research describes investigations of a 
subset of the Group A antibodies, M6143 and 2A9, and the singular Group B antibody B136. 
3.2 Research Aims 
Structural characterization of the isolated C1 domain of hFVIII in complex with inhibitory 
antibodies could reveal antibody epitopes in atomic detail, and enhance the knowledge of the C1 
domain’s function in hemostasis. Complexes were formed between recombinant C1 and the 
antigen-binding fragments (Fab) of the anti-C1 monoclonal antibodies (Mab) M6143, 2A9, and 
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B136. Hanging drop vapor diffusion was attempted to coax solution protein complexes to form 
sufficient quality crystals capable of X-ray diffraction. 
3.3 Materials and Methods 
3.3.1 Materials 
3.3.1.1 Expression Vector 
The pET-32a-c(+) plasmid was purchased from Novagen. Restriction enzymes BamH1 and Xho1 
were purchased from New England Biolabs (NEB). SHuffle K12 cells were purchased from NEB 
(Cat.# C3026J). Plasmid DNA preps and overnight aliquots of Lysogeny Broth (LB) (1% tryptone 
(w/v), 1% NaCl (w/v), 0.5% yeast extract (w/v)) were shaken in a ThermoScientific MaxQ 4000 
(Cat.# SHKE4000). The bacterial 1 L growth solutions were shaken in a New Brunswick Scientific 
Excella E25. Plasmid preps were completed with QIAGEN Qiaprep Spin Miniprep Kit (Cat.#: 
27106). Super Optimal Broth with Catabolite repression (SOC) media (2% tryptone (w/v), 0.5% 
yeast extract (w/v), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose) was prepared on 
site. The transformation selection ampicillin / LB-agar plates (1% tryptone (w/v), 1% NaCl, 0.5% 
yeast extract, 1.5% agar, 50 µM ampicillin sodium salt) were prepared in lab. 
3.3.1.2 Growth and Expression 
The LB media and the Terrific Broth (TB) media (2.4% yeast extract (w/v), 1.2% tryptone (w/v), 
0.4% glycerol (w/v), 0.23% KH2PO4, 1.64% K2HPO4) were prepared in-house. Ampicillin sodium 
salt (BioReagent grade) was purchased from Sigma Aldrich (Cat.# A0166-25G). Non-filter, non-
sterile SureOne™ 2 µL, 200 µL, 1000 µL pipette tips were purchased from Fisherbrand™ (Cat.# 
(0.1-10 µL) 02-707-137, (0.5-200 µL) 02-707-415, (100-1250 µL) 02-707-407). Bacterial growth 
optical density was assessed on a VWR Spectrophotometer V-122, with samples in plastic 
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disposable cuvettes purchased from BRAND GMBH (Cat.# 759075D). Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from Sigma-Aldrich (Cat.# I6758-10G). 
3.3.1.3 Cell Lysis 
Cells were pelleted from TB media by centrifugation on a ThermoFisher F12x6-500Y rotor and 
Sorvall Lynx 4000 preparatory centrifuge. Lysis buffer (300 mM NaCl, 20 mM 
tris(hydroxymethyl)aminomethane (Tris) (pH 7.5), 10% glycerol (w/v), 10 mM imidazole (pH 8.0), 
0.1% Triton X100 (w/v), 0.45 μm cellulose acetate membrane filtered) was prepared in house. 
Pelleted cells were resuspended by vertical mixing in a Benchtop Lab Systems Vertical Rotating 
Mixer, model VM-80. Cells were sonicated with a Branson Ultrasonics - Sonifier 450 (Power 
Setting 5 and Duty Cycle 50%). Insoluble cell debris was separated from soluble proteins by 
centrifugation with a Sorvall Lynx 4000 centrifuge and ThermoFisher F20-12x50 LEX 096-124375 
rotor. Buffer solutions and cellular lysate were filtered through Whatman cellulose acetate 
membranes (Cat.# 10404112). 
3.3.1.4 Protein Purification  
The gravity columns used were Kontes Flex-Columns of various height. The Wash I buffer (150 
mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol (w/v), 10 mM imidazole (pH 8.0), 0.45 μm cellulose 
acetate membrane filtered), Wash II buffer (150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol 
(w/v), 50 mM imidazole (pH 8.0), 0.45 μm cellulose acetate membrane filtered), Wash III buffer 
(150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol (w/v), 100 mM imidazole (pH 8.0), 0.45 μm 
cellulose acetate membrane filtered), Elution buffer (150 mM NaCl, 20 mM Tris (pH 7.5), 10% 
glycerol (w/v), 150mM imidazole (pH 8.0)), and Dialysis/Storage buffer (150 mM NaCl, 25 mM 
Tris (pH 7.5), 10% glycerol (w/v)) were prepared in-house. The TALON Co2+ resin, Ni-IDA resin, 
and Ni-NTA resin were purchased respectively from Takara Bio USA (formerly Clontech) (Cat.# 
30 
 
635503); UBP Bio (Cat.# P3010-25); and Qiagen (Cat.# 30210). Concentrations of protein were 
calculated with a BioTek Epoch Microplate Spectrophotometer. 
3.3.1.5 Chromatography Metal Charging Procedure 
HiTrap Chelating HP columns were purchased from GE Healthcare Lifesciences (Cat.#17040801). 
Candidate cation solutions were filtered with Whatman nylon membranes (Cat.# 7402-004). 
3.3.1.6 Enterokinase Cleavage of Thioredoxin-Hexahistidine Tag 
Recombinant Enterokinase (rEK), Enterokinase affinity resin (rEKapture agarose), and rEK 
cleavage buffer were purchased from Millipore Sigma (Cat.# 69067-3). Tabletop centrifugation 
was performed on a Sorvall Legend X1R. Eppendorf reactions were centrifuged using an 
Eppendorf® 5415D centrifuge and F45-24-11 rotor. The affinity resin was separated with a Costar 
Spin-X® 0.22μm cellulose acetate centrifuge tube filter (Cat.# 8161). Concentration and non-
dialysis buffer-swapping of protein was accomplished with Amicon Ultra spin concentrators. 
3.3.1.7 Anti-C1 Hybridoma Growth 
All mammalian cell research was performed in a Holten LaminAir HH72 tissue culture hood. 
Hybridoma cells were grown in Clonacell-HY hybridoma growth Medium E (MedE) from 
STEMCELL Technologies Incorporated. Dimethyl sulfoxide (DMSO) for mammalian cell 
cryoprotection was purchased from Sigma Aldrich (DMSO Hybri-Max, (Product #D26250-
100mL). The conical centrifuge tubes employed were Corning propylene, plug-seal 15 mL (Ref.# 
430052) and 50 mL (Ref.# 430290) units. Mammalian cell growth proceeded in Corning 75 cm2 
(“T-75”) C/N vent-cap flask (Ref# 3290). Large-scale mammalian cell growth occurred in triple-
layer ThermoScientific Nunclo Delta Surface flasks (Cat.# 132867). Mammalian cell growth 
occurred in Tabai ESPEC Corporation (Model BNA210) and Forma Scientific (Model 3546) CO2 
incubators, with USP Medical Grade CO2 gas from Airgas® Corporation (Cat.# UN1013). Solution 
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volumes were pipetted with a Falcon® Pipet Controller (Cat.# 10028-602). Cell culture volumes 
were transferred with Falcon 2 mL (Cat.# 357507), 10 mL (Cat.# 357551), 25 mL (Cat.# 357525), 
and 50 mL (Cat.# 357550) serological pipettes. 
3.3.1.8 Mammalian Cell Assessment 
Mammalian cell density was assessed with iNCyto C-Chip Neubauer Improved (DHC-N01-5) 
hemacytometer slides. Microscopy was performed on an Olympus IM cell tissue culture 
microscope. 
3.3.1.9 Anti-C1 Hybridoma Expression 
Versene (Gibco™) dissociation media was purchased from Fisher Scientific (Cat.# 15-040-066). 
Hybridoma expression occurred in CD Hybridoma Media (Gibco™) purchased from Fisher 
Scientific (Cat.# 11-279-023).   
3.3.1.10 Anti-C1 Hybridoma Mab Purification 
Sulfopropyl (SP) Fastflow™ ion exchange (IEC) resin was purchased from GE Healthcare Life 
Sciences (Prod.# 17-0729-01). The IEC “Buffer B” recipe (10 mM 2-ethanesulfonic acid (MES), 
20 mM NaCl, 0.05% NaN3 (w/v), pH 6.0) and IEC “Buffer C” recipe (20 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 0.05% NaN3 (w/v), pH 7.4) were 
prepared in-house. The IEC “Buffer A” recipe (100 mM MES, 200 mM NaCl, 0.05% NaN3 (w/v)) 
was used as a 10x stock for “Buffer B”. Cell centrifugation was accomplished with a 
ThermoScientific Sorvall Legend X1R.  
3.3.1.11 Anti-C1 Fab Generation by Immobilized Papain  
Fab cleavage from Mabs was accomplished with ThermoFisher Scientific Immobilized Papain 
agarose resin (Prod.# 20341). Papain Sample Buffer (20 mM NaPO4, 10 mM 
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ethylenediaminetetraacetic acid (EDTA), pH 7.0) and Papain Digestion Buffer (20 mM NaPO4, 20 
mM cysteine • HCl, pH 7.0) were prepared on site.  
3.3.1.12 Fab Protein A Purification 
The papain-cleaved Fabs were isolated by Protein A affinity chromatography with 
ThermoScientific Nab Protein A plus Spin kits (Prod.# 89948). Protein A Binding Buffer (100 mM 
K2PO4, 150 mM NaCl, pH 7.2, 0.05% NaN3 (w/v), 0.45µm cellulose acetate membrane filtered), 
Protein A Neutralization buffer (1 M Tris·HCl), and Protein A Resin PBS Storage Buffer (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8mM KH2PO4, 0.02% NaN3 (w/v), 0.45 µm cellulose 
acetate membrane filtered) were prepared in-house. The Protein A IgG Elution buffer (pH 2.8) was 
supplied in the manufacturer kit. 
3.3.1.13 Biolayer Interferometry of C1 and Anti-C1 Mabs 
Biolayer interferometry (BLI) assays were completed on a Pall FortéBio®  BLItz instrument. The 
BLI tips used to bind anti-C1 antibodies were Anti-Mouse IgG Fc Capture (AMC) (Cat.# 18-0025). 
Kinetics were measured using BLItz Pro software, version 1.1.0.31. Concentrations of protein were 
calculated with a BioTek Epoch Microplate Spectrophotometer.  
3.3.1.14 C1:Fab Crystal Trials 
The 24 well crystal trays were purchased from Hampton Research. The conditions used for protein 
crystallography included Hampton Research’s Index 1-96 kit (HR2-144), as well as the “Et3i trial 
B2”i and “B2(D2)35,45,47”ii tray conditions. Al’s Oil (50% paraffin oil, 50% silicone oil) was 
purchased from Hampton Research. Crystals were exposed to X-rays on a Rigaku Micromax-
007HF rotating anode generator and diffraction measured with a Saturn 994+ CCD area detector 
                                                     
i (Ian Wesley Smith (IWS)(II)p.100) 
ii (IWS(II)p.122) 
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in conjunction with the Stoddard lab at the Fred Hutchinson Cancer Research Center. Protein 
crystals were cryoprotected with BioReagent grade Hybri-Max™ dimethyl sulfoxide (DMSO) from 
Sigma Aldrich (Ref.# D2650-100ML).  
 
3.3.2 Methods  
3.3.2.1 Expression vectoriii 
Expression from the pET-32a-c(+) plasmid is under control of the lac operon and produces the 
FVIII C1 domain protein of interest with an N-terminal thioredoxin (“Trx•Tag”) fusion partner 
(Figure 24). To prepare the vector transformation, competent ShuffleK12 strain (NEB) E. coli were 
thawed on ice for 10 minutes. Then, 5 μL of 10.5 ng/mL pET-32a-c(+) plasmid DNA were added 
to the ShuffleK12 cells and allowed to incubate on ice for 30 minutes. The sealed mixture was 
submerged in a 42 °C water bath for precisely 30 seconds, and then returned to ice for 5 minutes. 
Subsequently, 950 μL of SOC media were added to the mixture and shaken at 250 rotations per 
minute (RPM) at 30 °C for 60 minutes. Several 10 fold serial dilutions were made of the cells and 
were plated on LB-ampicillin agar plates and grown overnight at 30 °C.  
Additional stock of C1 pET-32a-c(+) plasmid was produced by inoculating 10 mL of LB 
with C1 pET-32a-c(+) SHuffle K12 cells, and shaking at 150 RPM at 37 °C overnight. The plasmid 
was isolated using QiaPrep Spin MiniPrep (QIAGEN) kit instructions. 
                                                     
iii (IWS(I)p.81) 
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3.3.2.2 Growth/Expressioniv 
The day before a standard 6 L growth, six 10 mL aliquots of LB and six 1 L solutions of TB were 
prepared and autoclaved at 124 °C for 70 minutes. Once the autoclaved solutions had cooled to 
approximately 25 °C, the bacterial resistance selection agent ampicillin sodium salt was added to 
the LB and TB solutions to a final concentration of 50 μg/mL (Amp50). Aliquots of LB were 
inoculated with C1/ShuffleK12 cells by submerging a sterile p200 pipette tip into partially thawed 
cell stock and dispensing the tip into the LB solution. The inoculated aliquots were shaken at 37 °C 
for at least 18 hours, until visibly turbid. On the day of the growth, a 1 mL sample of TB was taken 
as an optical density blank, and each liter of TB was inoculated with 10 mL of the LB containing 
C1/SHuffle K12 cells. Inoculated TB flasks were shaken at 150 RPM at 30 °C, and beginning four 
hours after inoculation the optical density of bacterial growth was assessed hourly at 600 nm 
wavelength light (OD600). Once an OD600 value of 0.4 - 0.8 was recorded, the shaking temperature 
was reduced to 15 °C. Then, 1 mL of 1 M isopropyl β-D-1 thiogalactopyranoside (IPTG) was added 
to induce protein expression, which occurred overnight for approximately 16 hours. 
                                                     
iv(IWS(I) p.126) 
Figure 24 The pET-32a-c(+) plasmid expression region sequence. The FVIII C1 domain protein of interest was 
inserted into the plasmid with BamH I and Xho I restriction enzymes. (Novagen) 
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3.3.2.3 Cell Lysisv 
Following expression, cells were separated from the supernatant by centrifugation for 10 minutes 
at 4 °C at a Relative Centrifugal Force (rcf) of 6371 x G using a ThermoFisher F12x6-500Y rotor. 
Exhausted TB media was decanted from the cell pellet and discarded. Cells were divided into 50 
mL conical centrifuge tubes, with ~15 mL of pelleted cells per tube. To each pellet, 20 mL of Lysis 
buffer were added. Cell pellets were resuspended in this mixture by vertical rotation at 4 °C for 30 
minutes. Lysis of bacterial cells occurred through ultrasonication on ice in three sets of 30 seconds, 
with 30 second rests in between. The cell lysate was transferred to a small centrifuge tube, and 
centrifuged for 1.5 hours at 4 °C and 17500 RPM. Centrifuged lysate supernatant was decanted 
from the insoluble cell pellet and filtered sequentially through 5 μm, 0.45 μm, and 0.22 μm cellulose 
acetate membranes.  
3.3.2.4 Protein Purificationvi  
The hexahistidine (“His-Tag”) containing C1 protein was purified from the bacterial lysate 
supernatant by immobilized metal affinity chromatography (IMAC) batch purification. In a gravity 
column, 2 mL of 50% slurry TALON immobilized Co2+ resin was equilibrated in at least 10 mL of 
Lysis buffer. The equilibrated TALON resin was collected and combined with the filtered bacterial 
lysate in a separate 125 mL Erlenmeyer and mixed slowly at 4 °C for 30 minutes. The lysate-resin 
mixture was returned to the gravity column. The flow-through lysate was collected, followed 
sequentially by twenty column-volumes (20 CV, or 40 mL) of Wash I buffer; 4 CV of Wash II 
buffer; and 2 CV of Wash III buffer. Next, 2 CV of Elution buffer was added to the column and 
allowed to equilibrate for 15 minutes prior to collection. Finally, an additional 10 CV of Elution 
buffer was added to the resin bed and allowed to elute at ~1 mL/minute to ensure complete elution 
of immobilized protein. Imidazole was removed from the solution of purified protein by dialysis 
                                                     
v (IWS(I)p.126) 
vi (IWS(I)p.108) 
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with Dialysis/Storage Buffer. If purity of protein sample was not sufficient after one round of 
IMAC purification, the IMAC purification scheme could be repeated until desired purity was 
achieved. 
3.3.2.5 Chromatography Metal Charging Procedurevii 
To troubleshoot poor IMAC affinity of C1, HP Hitrap Columns were charged with several 
candidate cations to determine optimum C1 fusion protein interaction. The following metal ion 
salts were charged onto 1 mL HP Hitrap Columns according to manufacturer instructions: 
(NiCl2)•6H2O, (CoCl2)•6H2O, ZnCl2, CuSO4•5H2O, FeCl3•6H2O. Metal ion-salts were dissolved in 
deionized distilled water (ddH2O) to a final concentration of 0.1 M, and solutions were 0.22 μm 
syringe filtered. To immobilize cations in the resin matrix, each HiTrap column was washed with 
10 mL of ddH2O using a sterile syringe and Luer lock attachment, followed by 10 mL of the 
respective metal solutions. The FeCl3 solution was immobilized at pH 3.0 to avoid precipitation of 
insoluble ferric (Fe3+) iron. After metal binding, the 1 mL HP Hitrap columns were washed with 5 
mL ddH2O. Next, 5 CV of Elution buffer was flowed over the column, followed by 5 CV of 
Dialysis/Storage Buffer. These prepared columns were employed in IMAC purifications as 
previously described. 
3.3.2.6 Enterokinase Cleavage of Thioredoxin and His-Tagviii 
Recombinant Enterokinase (rEK) was utilized to separate the C1 protein of interest from the 
thioredoxin fusion partner and intermediary His-Tag. The amino acid sequence Asp-Asp-Asp-Asp-
Lys is recognized by rEK and cleaved, leaving a seven amino acid “tail” in front of the C1 domain 
sequence (Figure 24). To accomplish this, 50 U (3.25 µL) of rEK was added to a sample tube 
containing 22.5 mL (0.5 mg/mL) of expressed fusion C1 sample at 4 oC. To this, 1 mL of 
                                                     
vii (IWS(I) p.138) 
viii (IWS(I) p.144) 
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concentrated 10x rEK cleavage buffer was added to a final concentration of 0.5x. The rEK and 
protein were incubated overnight at 4 oC for a total of ~14 hours.   
To remove rEK after the cleavage reaction, 2 mL of enterokinase affinity (rEKcapture) 
agarose resin 50% slurry was added to a SpinX-Costar filter Eppendorf tube and equilibrated in 1 
mL 1x Cleavage Capture Buffer and centrifuged for 5 minutes at 500 x G. The resin flow-through 
was discarded, and the resin was washed with 2 x 1 mL of C1 Dialysis/Storage buffer; centrifuged 
for 5 minutes at 500 x G each time. Equilibrated rEKcapture agarose resin was pipetted from the 
SpinX CoStar filter Eppendorf and added to the rEK + C1 protein solution and incubated for 15 
minutes at 25 °C with gentle mixing. The protein + EK + resin mixture was pipetted back to a Co-
Star SpinX centrifuge tube and centrifuged for 5 minutes at 500 x G and the flow-through collected. 
The resin was washed with 1 mL of Dialysis/Storage buffer, centrifuged for 5 minutes at 500 x G, 
and the flow-through volumes were pooled.  
To separate the cleaved Thioredoxin-His Tag from isolated C1, a secondary IMAC 
procedure was performed as described (page 35) with 2 mL of TALON immobilized Co2+ resin 
50% slurry. The cleaved C1 protein of interest was collected in the IMAC flow-through. Isolated 
C1 protein was concentrated to ~0.8 mg/mL with an Amicon 3000 kD MWCO spin filter. 
3.3.2.7 Anti-C1 Hybridoma Growthix 
In a sterile cell culture hood, 9 mL of Hybridoma Medium E (MedE) was placed into a 15 mL 
conical centrifuge tube. Hybridoma cells (1 mL aliquots, ~1 million cells/mL) stored at -80 °C in 
MedE and 10% dimethylsulfoxide (DMSO) were warmed in a 37 °C water bath for approximately 
60 seconds until just thawed. Cells were pipetted into the 9 mL MedE aliquot, and the centrifuge 
tube was capped and inverted several times gently. The cells were pelleted by centrifugation for 5 
minutes at 1000 RPM. The DMSO-containing supernatant was discarded, and the hybridoma cell 
                                                     
ix (IWS(I) p.148) 
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pellet was resuspended in 2 mL MedE and transferred to a separate T-75 flask containing 15 mL 
of MedE. This tissue flask was sealed with a vented cap and transferred to a sterile water bath 
incubator at 5% CO2 and 37 °C. An additional 25 mL of MedE was added to the T-75 flask after 
48 hours to a total volume of 42 mL. 
3.3.2.8 Mammalian Cell Assessmentx 
Observations of mammalian cell cultures were made daily. Cells were assessed for spherical shape, 
adherence to the T-75 surface, percentage of confluence, and presence of foreign organisms. A 
hemacytometer slide was used to assess the cell density at the time of cryopreservation or 
passaging. Cells to be counted were pelleted and resuspended in 10 mL of MedE. Then, 1 mL serial 
dilutions (1:1, 1:100, 1:1000) were made from this stock solution, and 200 μL dilution samples 
were loaded onto the hematocytometer. Cells were counted across 5 large hemacytometer squares, 
and the average cell per area was multiplied by the dilution factor to calculate the cell density. 
3.3.2.9 Anti-C1 Hybridoma Expression 
When cells reached ~80% confluence, the exhausted MedE (brown-red and turbid in appearance) 
was decanted from the adhered cells and discareded. To gently dissociate the cells from the T-75 
surface, 1 mL of Versene was washed over the cells and discarded, followed by 2 mL of Versene 
added to the flask and the flask placed in the 37 °C incubator for 2 minutes. Dissociated with light 
tapping, the cells were pipetted into a 50 mL conical centrifuge tube and centrifuged at 1100 RPM 
for 10 minutes. The Versene supernatant was removed from the cell pellet and discarded. The cell 
pellets were resuspended in a 25 mL wash of CD Hybridoma Medium, centrifuged at 1100 RPM 
for 10 minutes, and the CD Hybridoma wash was decanted and discarded. The cells were then 
resuspended in 5 mL CD Hybridoma Medium and transferred to a new T-75 cell culture flask 
                                                     
x (IWS(II)p.6,8,10,26,28,30,32) 
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containing 45 mL of CD Hybridoma Medium. Cell expression occurred for seven days, with daily 
observation to assess surface adherence and aliquots taken to validate expression by SDS-PAGE.  
3.3.2.10 Anti-C1 Hybridoma Mab Purificationxi 
In a gravity column, 16 mL of 50% slurry (8 
mL packed resin) of Sepharose Sulfopropyl 
FastFlow strong cation ion exchange 
chromatography (IEC) resin were equilibrated 
with 50 mL of “Buffer B”. The 50 mL aliquot 
of CD Hybridoma expression media 
containing anti-C1 Mab’s was diluted 4x with 
ddH2O (e.g. 50 mL Mab + 200 mL ddH2O) and 
adjusted to pH 5.5 - 6.0 with 8 mL of 0.5 M 
MES (pH unadjusted). The diluted Mab’s were 
loaded onto the IEC column overnight using a 
“siphon safety-loop” at 4 °C, and the flow-
through was collected (Figure 25). The column was washed with 50 mL of Buffer B with the wash 
collected separately. It was opted not to observe OD280 baseline reading during the wash step, due 
to lack of a UV spectrophotometer in the 4 °C cold room. To elute the bound anti-C1 Mab’s, 30 
mL of “Buffer C” were added to the column. The first 3 mL of eluent from the column and the next 
27 mL of eluent were collected as separate fractions. Eluted antibody fractions were concentrated 
with 15 mL Amicon Ultra 10 kD MWCO spin concentrators, and the presence of Mabs determined 
by SDS-PAGE.  
                                                     
xi (IWS(II)p.24, 36) 
Figure 25 Diagram of gravity chromatography with 
siphon-safety loop. A siphon draws the buffer through the 
column. A section of the pre-column loop remains below 
the level of eluent outflow. When the buffer volume runs out 
the siphon will stop and the column will not run dry. This 
allows for unattended loading of the chromatography 
column. 
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3.3.2.11 Anti-C1 Fab Generation by Immobilized Papainxii 
To generate anti-C1 Fab fragments, the purified Mab samples were dialyzed into “Papain Sample 
Buffer” by dialysis tubing membrane overnight at 4 °C. Several times, EDTA was erroneously 
omitted from the Papain Sample Buffer preparation. The Mab sample was concentrated to 
approximately 20 mg/mL. Just before use, the “Papain Digestion Buffer” was prepared. Then, 0.5 
mL of Digestion Buffer was combined with 0.5 mL of antibody sample, and the 1.0 mL reaction 
volume was then added to 0.5 mL of 50% slurry Immobilized Papain resin equilibrated in Papain 
Sample Buffer. Once the reaction was completed from 5-24 hours, the agarose resin was removed 
by a Co-Star Spin X filter Eppendorf and the supernatant mixture of Fc and Fab’s collected. 
Cleavage by immobilized papain was verified by SDS-PAGE.  
3.3.2.12 Fab Protein A Purificationxiii 
Bacterial Protein A binds tightly to IgG antibody Fc regions, and can be used to purify antibody 
Fabs. The 500 µL Immobilized Protein A columns were equilibrated in Protein A Binding Buffer 
according to manufacturer instructions. Next, 500 µL of papain-cleaved antibody sample was added 
to the column and gently shaken for 10 minutes at 25 °C. The unbound supernatant was removed 
by centrifugation at 5000 x G for 2 minutes. The column was washed in triplicate with 400 µL 
aliquots of Protein A Binding Buffer and centrifugation at 5000 X G for 1 minute. Then, the Fab 
of interest was eluted in from the column with triplicate 400 µL aliquots of Protein A Elution Buffer 
added to the resin, mixed gently for 1 minute, and removed by centrifugation at 5000 X G. Each 
elution was collected into separate Eppendorf tubes, containing 40 µL of Protein A Neutralization 
Buffer. Protein A purification was validated by SDS-PAGE. 
                                                     
xii (IWS(II)p.60) 
xiii (IWS(II)p.62) 
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3.3.2.13 Biolayer Interferometry of C1 and Anti-C1 Mabsxiv 
Affinities of the murine-derived anti-C1 monoclonal antibodies were determined by biolayer 
interferometry. To complex C1 and Mab’s in stoichiometric amounts, each was diluted to 300 nM 
and combined in equal volumes. FortéBio goat-derived anti-mouse IgG Fc Capture (AMC) 
Biosensor sample tips were hydrated in Dialysis/Storage buffer for 15 minutes. BLItzPro software 
“Advanced Kinetics” experiment template, five-phase trials (Baseline 30 seconds, Mab Association 
300 seconds, Baseline 30 seconds, C1 Association 300 seconds, C1 Dissociation 300 seconds) were 
undertaken for each anti-C1 Mab. Negative controls for C1 and Mab’s were performed for each 
C1:Mab pair. Kinetics for Mab binding were automatically calculated by the BLItzPro software. 
3.3.2.14 C1:Fab Crystal Trialsxv 
To pursue a molecular model of the FVIII C1 domain in complex with inhibitory antibodies, 
crystallization of isolated C1 domain and antibody Fab fragments was attempted. The concentration 
and extinction coefficient of pure C1 and 2A9 Fab was determined by Bradford assay and 
confirmed via light absorbance at 280 nm (A280). Enterokinase cleaved C1 was complexed with 
2A9 anti-C1 Fab fragments in stoichiometric amounts in an Eppendorf tube and allowed to sit on 
ice for 10 minutes. The mixture was pipetted into a 4 mL Amicon spin concentrator and centrifuged 
at 3000 rpm for 10 minutes. The mixture was transferred to a 15 mL conical tube and centrifuged 
at 3000 rpm for 5 minutes to pellet any aggregate. 
The 24-well crystal trays were greased in-house. Each well was ringed with petroleum jelly 
using a 10 mL syringe fitted with a Leuer-lock needle tip, leaving a small gap (~1 mm) in the grease 
ring to allow air to escape when pressing down the coverslip for proper sealing. Following this, 400 
µL of mother liquor was added to each well. On a 18 mm siliconized glass cover slide, 2 µL of 
mother liquor was pipetted into a 2 µL droplet of protein complex sample. 
                                                     
xiv (IWS(I)p.15,19,23) 
xv (IWS(III)p.4) 
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Next, 400 µL of Al’s Oil (50% paraffin oil and 50% silicone oil) was added to the mother 
liquor in the well to reduce the rate of vapor diffusion. The cover slide was then inverted (with the 
droplet hanging down) and pressed into the ring of grease to form a hermetic seal. Once all 24 wells 
were completed, the trays were gently relocated to a quiet location and placed on a 2” layer of 
insulation foam for up to 4 weeks before inspection. Crystals that formed were cryoprotected 
sequentially in solutions containing 10%, 20%, and 30% DMSO. 
3.4 Results 
3.4.1 Plasmid Prepxvi 
Previous researchers inserted the cDNA for the isolated C1 domain of hFVIII, consisting of 148 
residues, into a pET-32a-c(+) plasmid using the BamH1 and Xho1 restriction enzyme cleavage 
sites. The C1-fusion-containing pET-32a-c(+) plasmid was transformed into competent SHuffle 
K12 cells. 
3.4.2 Growth, expression, and purification of recombinant FVIII C1 domain. 
Expression of recombinant FVIII C1 domain 
from pET-32a-c(+) plasmid in bacterial 
SHuffle K12 cells was visualized by SDS-
PAGE, identifying a Thioredoxin-C1 fusion 
protein band at approximately ~34 kD 
migration. Approximately 6 mg of IMAC 
purified thioredoxin-C1 fusion protein was 
yielded for a typical 6 L growth prep in TB 
media (Figure 26). 
                                                     
xvi (Laurel Sugden (LAS)(I)p.3) 
Figure 26 C1 IMAC Purification. (3.24.2017) The 15% 
acrylamide SDS-PAGE gel visualization of the ~36 kDa 
Thioredoxin-C1 fusion protein expressed from pET32-a-
c(+) plasmid in SHuffle K12 cells. The imidazole content 
of Washes I-III and Elution buffer were 10 mM, 50 mM, 
100 mM, and 150 mM, respectively. 
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To avoid interference with antibody binding experiments, the N-terminal thioredoxin 
fusion protein and hexahistidine tag were removed from C1 by enzymatic cleavage with 
recombinant enterokinase (rEK). Cleavage and separation of the Thioredoxin-C1 fusion protein by 
enterokinase was generally successful. However, the IMAC separation of the ~11 kD Thioredoxin-
His-Tag and ~16 kD C1 components was often ineffective, requiring extensive dialysis for 
successful IMAC separation (Figure 27). The approximate purity of C1 after the secondary IMAC 
was ~70%. Purity increased to ~80% following secondary IMAC preparatory steps (Figure 28). 
Optimization of the C1 IMAC affinity with candidate cations was attempted, with no 
improvement observed and some cations failing to bind His-tagged protein (See Appendix: Figure 
50, Figure 51, Figure 52, Figure 53, Figure 54).  
3.4.3 Growth, expression, and purification of anti-C1 Mabs and generation of anti-C1 Fabs 
Murine hybridomas expressing “Group A” (M6143 and 2A9) and “Group B” (B136) anti-C1 
antibodies were successfully cultured (Figure 29). The hybridomas were passaged into larger flask 
Figure 27 C1 Fusion Enterokinase Cleavage. The C1 
fusion construct was cleaved by recombinant 
enterokinase (rEK) to remove the ~11 kDa thioredoxin 
and hexahistidine tag. Post rEK cleavage, the rEK was 
removed with rEKcapture affinity agarose. (4.12.2017) 
Figure 28 Sequential IMAC Purifications of C1 fusion 
protein. The second IMAC round was performed to achieve 
desired purity of recombinant protein. (9.18.2017) 
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growths, and the expressed monoclonal antibodies were separated from the cells and expression 
media by cation-exchange chromatography (IEC) (Figure 30). 
3.4.4 Production of Fabs from Mabsxvii 
Anti-C1 Mabs were enzymatically cleaved by immobilized papain resin to generate respective Fab 
fragments for protein crystallography trials. Incomplete cleavage of Mabs was observed. Following 
cleavage by papain, the Fab fragments were successfully separated from the undesired 
crystallizable fragment (Fc) by Protein A affinity chromatography (Figure 31). The concentration 
of the Fab sample was determined by Bradford assay (Figure 32). The extinction coefficient of 2A9 
Fab was calculated to be 21400 𝐿𝑚𝑜𝑙−1𝑐𝑚−1(1% solution). 
                                                     
xvii (IWS(III)p.7) 
Figure 29 Hybridoma cells (2A9) viewed at 400x 
magnification (95% confluence). Confluence was assessed 
at 100x magnification. (7.28.2017 IWS(II)p.64) 
Figure 30 Hybridoma purification by ion-exchange 
chromatography (IEC). The Group A antibodies M6143 
(lanes 2,3), 2A9 (lanes 5,6), and Group B antibody B136 
(lanes 8,9) demonstrated differing expression levels. 
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3.4.5 Biolayer Interferometry of C1 and Anti-C1 Mabs 
Binding affinities of Group A (2A9, M6143, I41, I84, I88, B153) and the Group B (B136) 
antibodies were measured via BLI. The antibodies which demonstrated reproducible kinetics, 
Group A antibodies (M6143 and 2A9) and Group B (B136) underwent additional titrations of C1 
to establish a dose-dependent binding curve (Table 1, Appendix B: Figure 55, Figure 56, Figure 
57). 
 
Figure 32 Anti-C1 2A9 Fab Bradford Assay. Gamma 
globulin (IgG) (2ug/uL) was used as a control standard. 
(11.21.2017 IWS(III)p.7) 
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Figure 31 IgG 2A9 Fab Protein A Purification. The 
presence of 25 kD protein in the flow through and wash 
(lanes 1 and 2) were assumed to be IgG Fab. The 50 
kD elution bands (lanes 7-9) indicate incomplete 
cleavage of Mabs by the immobilized papain resin. 
(11.13.2017 IWS(II)p.118) 
Table 1 BLI Determined Anti-C1 Antibody Affinities. Data calculated by ForteBio BLItzPro. 
Date Mab Group ka (1/Ms) kd (1/s) KD (M) Rmax
11.2.2016 M6143 A 1.43E+07 1.00E-07 1.00E-12 0.00E+00
11.22.2016 2A9 A 7.82E+06 1.64E+06 2.10E-01 -1.43E+03
11.11.2016 B136 B 1.79E+01 1.96E-02 1.10E-03 7.16E+02
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3.4.6 C1:Fab Crystal Trials 
 2A9 Fab fragments were complexed with 
isolated C1 protein. The concentrated mixture 
(~0.37 mg/mL) was screened in hanging drop 
vapor diffusion crystal trials. Initial crystal hits 
in the #82 Index well (0.2 M MgCl2·6H2O, 0.1 
M Bis-Tris pH 5.5, 25% w/v polyethylene 
glycol (PEG) 3350) and #83 Index well (0.2 M 
MgCl2·6H2O, 0.1 M Bis-Tris pH 6.5, 25% w/v 
PEG 3350) were negative for diffraction 
(Figure 33)xviii.  
3.5 Discussion 
3.5.1 Bacterial Expression and Purification of Isolated C1 domain. 
Several obstacles were encountered during the expression of isolated C1 domain of blood 
coagulation Factor VIII that should be noted in future work. The expression of C1 was lower yield 
and less well-behaved than the isolated domain of C2. One complication during purification was 
the early elution of the C1 fusion protein from IMAC resin upon introduction of the 50 mM 
imidazole Wash II buffer (Figure 26 (Lane 3), page 42). In practice, the Wash II and Wash III 
buffers were commonly omitted to maximize the retention of the C1 fusion in the eluent, at the 
price of reduced purity of the protein of interest. This reduced IMAC affinity was noted on all 
IMAC resins attempted. Poor cation affinity may be caused by the internal placement of the 
hexahistidine tag between the thioredoxin and recombinant C1 domain (Figure 24, page 34).  
                                                     
xviii IWS(II)p.151 
Figure 33 Non-diffracting crystals of complexed C1 and 
2A9 Fab. These crystals did not diffract X-rays in a 
manner indicative of a biological molecule, and were likely 
salt complexes. (12.18.2017 IWS(III)p.4) 
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Post-enterokinase cleavage, the separation of the C1 domain from the thioredoxin-
hexahistidine tag was difficult. The issue could stem from the use of diafiltration instead of dialysis 
to remove imidazole after the primary IMAC purification. Reduced efficacy in imidazole removal 
could explain the thioredoxin-hexahistidine band in the post-EK cleavage flow-through. (IWS (I) 
145) (Figure 27 (Lanes 6 and 8)) 
Compared to recombinant FVIII C2 domain, the C1 domain exhibited decreased solubility 
above 1.0 mg/mL, especially once cleaved from its thioredoxin fusion partner. This behavior could 
result from differences in the increased hydrophobic face of isolated C1, which normally packs 
against the A3 domain of FVIII. The solubility of isolated C1 may be optimized with addition of 
zwitterionic or neutral detergents, but requires further investigation. 
3.5.2 Mammalian Cell Growth and Expression of Antibodies  
Mammalian cell culturing of anti-C1 antibodies were successful, however, several troubleshooting 
points and opportunities for improvement exist for the expression and purification procedures. It 
was observed that the three hybridoma strains (M6143, 2A9, and B136) exhibited significantly 
different character in the rate of proliferation, strength of adherence to the flask surface, expression 
of antibody, and vulnerability to stress and apoptosis. Of the three, 2A9 grew appreciably faster, 
reaching confluence in little over 48 hours. B136 was much slower in proliferation and susceptible 
to displaying cell stress morphologies, but highly adherent. M6143 was well behaved and seemed 
to express antibody at much higher levels than either 2A9 or B136. 
Higher standards of cleanliness and sterility should be observed in the future when 
culturing mammalian cells. Several instances of contamination with fungus occurred. While not 
directly detrimental to the mammalian cells, the foreign organisms compete for media nutrients and 
likely complicate purification. The risk of contamination can be minimized through the addition of 
a fungicide to the mammalian medium, regular preventive maintenance and cleaning of equipment, 
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and increased observance of gloves and lab coats while working in the tissue culture room  
(Figure 34).  
It was observed that papain cleavage 
of Mabs to produce Fabs consistently 
displayed incomplete reaction with Mabs. This 
could have stemmed from the erroneous 
omission of EDTA in several preparations. 
Alternatively, the reaction took place in an 
upright Eppendorf tube on a shaker table. The 
immobilized papain resin settled to the bottom 
of the reaction vessel, despite attempts to 
resuspend it or shake the Eppendorf tube at an 
angle. As a result, insufficient resin-bound papain exposure with the Mab solution may have 
occurred. In the future, use of a specialized reaction vessel or attempting an immobilized papain 
cleavage in an Erlenmeyer flask with gentle stirring is recommended. Additionally, due to limited 
Mab material these reactions were performed below the manufacturer recommended concentration 
of 10 mg/mL. This could detrimentally affect reaction efficiency and require additional time for 
papain cleavage to occur.  
3.5.3 Biolayer Interferometry of C1 and Anti-C1 Mabs 
The BLI studies showed that recombinant C1 interacted with expressed Mabs in a dose-dependent 
manner, with increased binding detected for increasing stoichiometric ratios of C1, including 0.5 : 
1 (150 nM C1: 300 nM Mab), 1 : 1 (300 nM C1: 300 nM), 1.33 : 1 (400 nM C1 : 300 nM Mab), 
and 2 : 1 (600 nM C1 : 300 nM Mab)(Table 1,Appendix B: Figure 55, Figure 56, Figure 57). 
However, in comparison to previous surface plasmon resonance (SPR) data,99 discrepancies are 
apparent (Table 2). Differences in the calculated association rate (ka), dissociation rate (kd), and the 
Figure 34 Fungal contamination of B136 hybridoma cells. 
The foreign organisms appeared after several passages of 
hybridoma cells were completed. 
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equilibrium dissociation constant (KD) kinetics could stem from the sensitivity of the 
instrumentation, or the purity of the recombinant C1 protein preparation. Additionally, the use of 
10% glycerol Dialysis/Storage buffer in BLI studies could cause a mass-transport effect, 
detrimentally affecting binding data. In the future, higher purity of recombinant C1, and a 0.5% 
glycerol buffer stabilized with detergents should be attempted. 
Table 2 Comparing SPR (Batsuli et al.) and BLI Determined Anti-C1 Antibody Affinities 
M6143 and C1 ka (1/Ms) kd (1/s) KD (M) Rmax 
SPR Data (Batsuli) (0.5 ± 0.2)e6 (0.9 ± 0.1)e-4 2.00E-10 132.8 ± 25.3 
BLI Data (Spiegel) 1.43E+07 1.00E-07 1.00E-12 0.00E+00 
2A9 and C1 ka (1/Ms) kd (1/s) KD (M) Rmax 
SPR Data (Batsuli) (0.3 ± 0.1)e6 (2.2 ± 0.2)e-4 9.00E-10 97.8 ± 1.1 
     
BLI Data (Spiegel) 7.82E+06 1.64E+06 2.10E-01 -1.43E+03 
B136 and C1 ka (1/Ms) kd (1/s) KD (M) Rmax 
SPR Data (Batsuli) (3.1 ± 1.2)e6 (3.2 ± 0.4)e-4 1.00E-10 301.9 ± 26.5 
BLI Data (Spiegel) 1.79E+01 1.96E-02 1.10E-03 7.16E+02 
 
3.5.4 C1:Fab Crystal trials 
The enterokinase cleaved recombinant C1 protein and 2A9 anti-C1 Fab complex were screened 
against the Hampton Research Index (HR2-144) conditions. Several initial crystal hits of C1:Fabs 
collected did not display diffraction properties akin to biological macromolecular crystals, and were 
likely small molecular salts. The crystal conditions for the C1:2A9 complex requires additional 
development.   
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Chapter 4: Structural Modeling of Human Porcine Chimeric Et3i 
4.1 Introduction 
The development of anti-FVIII inhibitory alloantibodies, known as “inhibitors”, represents a major 
complication of hemophilia A treatment. The standard remedy to negate inhibitors is immune 
tolerance induction (ITI), whereby large infusions of FVIII overwhelm the immune response. The 
significant cost of ITI102 is elevated by the fact that FVIII has a low endogenous serum 
concentration of ~0.5 nM,47 and has proven refractory to recombinant production. Due to the large 
quantity of FVIII required for ITI campaigns, development of a high-yield recombinant human 
FVIII (rhFVIII) is of significant interest to the hematological community. It has been demonstrated 
that recombinant B-domain-deleted (BDD) porcine FVIII (rpFVIII) expresses at 10-14 fold higher 
levels than rhFVIII.62 A novel human/porcine chimeric construct (“Et3i”) containing the porcine 
A1 and A3 domains expresses 5.3 ± 0.75 fold higher than rhFVIII from transiently transfected 
COS-7 and stably transfected BHK cells, while maintaining comparable clotting activity.63 Et3i has 
received positive feedback from an FDA Pre-Investigational New Drug (IND) program and is 
additionally being evaluated as a potential gene therapy candidate.63–65 
Structural modeling of Et3i could aid in the development of less-immunogenic protein 
therapies and would improve upon the already published, intrinsically low-resolution FVIII 
structures (PDB: 2R7E103, 3CDZ104). In addition to clinical applications, characterizing the atomic 
structure of Et3i could supplement fundamental understanding of the architecture and activity of 
human and porcine FVIII. In particular, when FVIII is cleaved to the activated heterotrimeric state 
(A1/A2/A3-C1-C2), the rate at which the A2 domain dissociates from its A1/A3 interface is 
strongly correlated to the lifespan of the protein in serum.53,71 It has been demonstrated that pFVIII 
has increased stability of the A2 domain in the heterotrimeric state. Structural modeling of the 
interactions between the porcine A1 & A3 and human A2 domains could lead to knowledge of 
additional stabilizing mutations to and development of future therapeutics.  
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4.2 Research Aims 
Structural characterization of the human/porcine chimeric FVIII construct “Et3i” could further 
understanding of the development of inhibitory antibodies and FVIII domain-domain interactions. 
To accomplish this, protein crystals of purified Et3i formed by hanging drop vapor diffusion were 
exposed to X-rays and their diffraction pattern measured. A data set describing the electron density 
map of the crystallographic asymmetric unit was generated, and a molecular model was refined by 
tools included in the WinCoot and Phenix software suites. Additionally, improved crystals were 
attempted with both unmodified and deglycosylated Et3i alone or in complex with the anti-C2 
antibody G99 Fab. 
4.3 Materials and Methods  
4.3.1 Materials 
4.3.1.1 Generation of 2014 Crystal and Data Set 
Protein crystals were exposed to X-rays from the synchrotron Advanced Light Source (ALS) at the 
Lawrence Berkeley National Laboratory. 
4.3.1.2 Et3i Model Refinement 
The Phenix (Version 1.12-2829) software suite was employed to solve the phase problem by Phaser 
molecular replacement (MR), and automatically refine the molecular structure and electron density 
map. Manual adjustment of the protein model into the refined electron density map was performed 
with WinCoot (Version 0.8.6.1).  
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4.3.1.3 Attempted Improvement of Et3i Crystals 
Crystal tray condition calculations were completed with Hampton Research’s Make Tray 
(https://www.hamptonresearch.com/make_tray.aspx). The 24 well crystal trays were purchased 
from Hampton Research. Crystal screen conditions used included Hampton Research PEG/Ion2 
(HR2-098) and Index (HR2-144). The rate of vapor diffusion to the mother liquor was reduced 
with Al’s Oil (50% silicone oil, 50% paraffin oil, Hampton Research). Deglycosylation of Et3i was 
performed by Remove-iT PNGaseF, New England Biolabs (Prod.# P07065). Remove iT PNGaseF 
was sequestered with Chitin Magnetic Beads, New England Biolabs (Prod.# E80365) and Clontech 
magnetic stand for Eppendorf tubes (Cat.# 631964). Attempted improved crystals were exposed to 
X-rays on a Rigaku Micromax-007HF rotating anode generator and diffraction measured with a 
Saturn 994+ CCD area detector in conjunction with the Stoddard lab at the Fred Hutchinson Cancer 
Research Center. 
4.3.2 Methods 
4.3.2.1 Generation of 2014 Crystal and Data Set  
Previous researchers employed hanging drop vapor 
diffusion to crystallize aliquots of Et3i in conditions 
(16% polyethylene glycol (PEG) 3350, 0 M MgCl2, 
0.025 M 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid) HEPES) with 
increasing PEG3350 across the tray X-axis (+(2%) 
/ column), and increasing MgCl2 down the tray Y-
axis (+(0.025 M) / row) (Figure 35). 
 
 
Figure 35 Stereotypical crystals of Et3i. 
Thin, trapezoidal crystals which layers of sheets were 
repeatedly obtained via hanging drop vapor diffusion. 
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4.3.2.2 Et3i Model Refinement  
X-ray diffraction data were indexed, integrated and scaled with the program XDS to 3.2 Å 
resolution. Molecular Replacement with Phaser MR (template model: 2R7E103) allowed for 
determination of the phase angles of X-ray diffraction data and generation of an electron density 
map. Manual adjustment of the protein model into the refined electron density map was performed 
with WinCoot. The Phenix software suite was employed to automatically refine the molecular 
structure and electron density map. The primary tool of refinement was the “phenix.refine” tool 
suite.94 Refinement configurations relied on rigid-body, XYZ coordinates, real-space, and 
Individual B Factor parameters. Rigid-body refinement locks the geometry of the molecule and 
optimizes the models fit into the electron density through translation and rotation functions. XYZ 
coordinate refinement allows for Cartesian manipulation of model geometry to match the X-ray 
data. Real-space refinement achieves a similar effect, but optimizes model geometry against the 
calculated electron density map, instead of X-ray diffraction data. The individual B factor 
refinement tool adjusts the calculated atomic vibrational equilibrium position, or “temperature 
factor” for each atom in the model. For this model, B factors were calculated as isotropic. Once 
glycans were appended to the model with the WinCoot Carbohydrate module, the Phenix ReadySet 
tool generated ligand restraints and LINK entries in the .pdb file before each phenix.refine cycle. 
ReadySet employs the program suite eLBOW and PhenixRefine to generate and optimize ligand 
structural parameters.105 
To address a structural shift observed in the Molecule B’s C2 domain, the Phenix suite tool 
“Morph Model” was employed; which restrained local relative positions between amino acid 
residues while allowing the domain as a whole to perform translation and rotation optimization 
functions.106,107 The Phenix suite Omit Map tool was employed to remove and generate a more 
indicative difference map for difficult external loops and the Molecule B C2 domain.108 The metrics 
of Rfree, Rwork validated the agreement between the molecular model and the crystallographic 
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electron density. The MolProbity suite tracked geometry of the model, tracking Ramachandran 
outliers, rotamer outliers, and steric clashes. 
4.3.2.3 Attempted Improvement of Et3i Crystalsxix 
To improve crystal quality, another Et3i prep (Expression Therapeutics, 6/5/2017, 0.84 mg/mL) 
was screened through crystallization trials. The starting 24-well tray crystal condition was reused 
from previous researchersxx ((16% polyethylene glycol (PEG) 3350, 0M MgCl2, 0.025 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) HEPES) with increasing PEG3350 across the tray 
X-axis (+(2%) / column), and increasing MgCl2 down the tray Y-axis (+(0.025 M) / row). Further 
optimizations included additions of Hampton Research (HR) Index Screen to HR PEG/ION2 
Screen conditions.xxi The percent (%) of PEG, and molarity (M) of MgCl2 and HEPES were 
controlled, so that the final concentration was held constant upon addition of the PEG/ION2 
conditions. This was accomplished with a functionalized Microsoft Excel spreadsheet of the 
following format:  
Table 3 Crystal Condition Control for PEG content. Assume a 5 mL crystal condition solution.   
 
                                                     
xix (IWS(II)p.89) 
xx (Anne d’Aquino (AD)(I) p.151) 
xxi (IWS(II)p.98,110,122) 
X
Original Volume (μL) New Vol.
1800  =1800-(((X)*(PEG % of X))/50)
260.4 260.4
312.5 312.5
462.5 462.5
X X
2164.6  =((2164.6-X)+(((PEG% of X)*X)/50))
SUM= 5000  =SUM()
Addtl. Vol. of PEG/Ion screen to add to PEG containing condition (μL)
Original PEG-Containing-Condition Chemical
ddH2O
Obsv:
50 % PEG 3350
0.96 M HEPES (8.26)
1.0 M MgCl2
100 % PEG 400
New PEG/Ion Screen
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Deglycosylation of Et3i with PNGase F was attempted to improve crystal quality.xxii The 
reaction was first optimized under native and denaturing conditions with dithiothreitol (DTT). The 
refolding of Et3i after denaturation was not assessed. 
Additionally, Et3i was complexed with the anti-C2 domain antibody G99 Fab (Et3i:G99) 
in stoichiometric amounts in an attempt to form protein crystals. 
4.4 Results 
4.4.1 Crystal Structure of Et3i  
The X-ray crystal structure of the human/porcine chimeric protein, “Et3i”, residues 1 - 
2329 was determined to 3.2 Å resolution and refined to an Rwork of 0.2146 and Rfree of 0.2879 
(Figure 36). Et3i was crystalized in a novel FVIII space group P21 compared to previously 
published FVIII models in P41212. Molecular replacement (MR) was accomplished using prior 
                                                     
xxii (IWS(II)p.58) 
Figure 36 Structure of Et3i Molecule A. This protein chimera contains porcine A1 and A3 domains (blue), and human 
A2, C1 and C2 domains (red). Metal ligands, calcium (green) and copper (magenta) are shown. Asparagine linked 
glycan ligands (teal) were modeled at N240, N1810, and N2118. 
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hFVIII as a template (PDB: 2R7E103). The model geometry for this FVIII construct is significantly 
more robust than previously published FVIII models. 
Two molecules of Et3i were observed in 
the asymmetric unit, molecules “A” and “B” 
(Figure 37). Each molecule contained three metal 
ligands, two copper and one calcium. The improved 
electron density allowed for greater confidence in 
modeling important structural elements. First, 
improvement of A1 domain metal coordination 
site, residues 316-318 (HHH) was accomplished. 
Additionally, the improved electron density 
allowed accurate placement of asparagine-linked 
glycans at residues N240 (Molecule A: N-NAG2-
BMA-MAN2; Molecule B: N-NAG2-BMA-
MAN2), N1810 (Molecule A: N-NAG2-BMA; 
Molecule B: N-NAG(FUC)-NAG-BMA-MAN4), and 
N2118 (Molecule A: N-NAG2-BMA-MAN2; 
Molecule B: N-NAG2-BMA-MAN2). 
Poor non-crystallographic symmetry (NCS) up to 14 Å was observed between the 
Molecule A and Molecule B C2 domains (Figure 38). Refinement with the Phenix MorphModel 
tool resolved a whole C2 domain “roll” of approximately 12 Å between the molecule A and B of 
the asymmetric unit (Figure 39).  
Figure 38 Spatial Comparison of Non-Crystallographic Symmetry (NCS) between Et3i Molecule A and B. The 
difference between Molecule A and Molecule B is reported in relative distance (Y-axis, Å) for each residue (X-axis). 
Well behaved data on the left (residue) ~1 Å difference. The molecule B C2 domain (right) ~11 A Å NCS distances. 
Figure 37 Two molecules in the Et3i asymmetric 
unit. A significant conformational difference was 
observed between the C2 domain of molecule A 
(red), and molecule B (cyan). 
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4.4.2 Rebuilding the hFVIII structure with ET3i Model 
Based on the observation that the newly solved ET3i model could be refined against the data sets 
for either previous hFVIII (2R7E or 3CDZ) structure factors and significantly improve the Rfree and 
Rwork, rebuilding the entire hFVIII structure based on the Et3i model was undertaken. Using the 
completed Et3i model as a template, an improved hFVIII model was constructed. This model 
contains the improved architecture of the Et3i molecule in hFVIII derived electron density data set 
in comparison to previously published FVIII models (PDB:2R7E103, 3CDZ104). The Et3i residues 
in the A1 and A3 domains were mutated to the human FVIII sequence in silico with WinCoot. 
When the new hFVIII model was refined against previous hFVIII data, the rebuilt model of hFVIII 
attained increased model accuracy with an improved Rfree of 0.2749 compared to previous Rfree 
0.347 (2R7E103).  
4.4.3 Attempted Improved Crystallization of Et3i, Et3i:G99, and PNGaseF  
Improvements to the 2014 crystal of Et3i were attempted, including a variety of trays and 
optimizations with a new prep of Et3i from Expression Therapeutics (6/5/2017, 0.8473 mg/mL) 
Figure 39 C2 Domain Comparison in Overlay of the Molecule A and B in Profile. The Et3i A & B molecules were 
aligned to each other in PyMol. With Molecule A and B overlaid, a ~10 Å rotation of the C2 domain was observed. 
Distances were measured between three arbitrary residues of the A / B molecule overlaid pair, including: L2252 (12.5 
Å), G2268 (10.7 Å), and N2277 (15.8 Å). 
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and anti-C2 domain G99 antibody Fabs. While small and well defined Et3i crystals were readily 
obtained, the trials but did not yield crystals of sufficient size or quality to diffract X-rays. 
PNGaseF was employed to deglycosylate asparagine-linked glycans from Et3i, by cleaving 
the innermost asparagine and N-acetylglucosamine bond.xxiii Cleavage of Et3i was successful, but 
the protein remained recalcitrant to crystallization (Figure 40). The three asparagine-linked glycan 
sites modeled in Et3i were at N240 (A1 domain), N1810 (A3 domain), and N2118 (C1 domain). 
The FVIII Heavy Chain (A1-A2) contains the 
N240 glycan site, while the FVIII Light Chain 
(A3-C1-C2) contains N1810 and N2118. 
Deglycosylated Et3i was complexed with Fabs 
of G99 in stoichiometric amounts, but crystals 
of sufficient size to diffract X-rays were not 
formed (Figure 41). Trays of glycosylated 
Et3i:G99 complex formed crystals, but none 
diffracted X-rays sufficiently to calculate an 
electron density map.xxiv 
 
  
                                                     
xxiii (IWS (II)p.56,126) 
xxiv (IWS(II)p.144) 
Figure 41 Morphologies of Deglycosylated Et3i Crystals. These crystals were exposed to X-rays and diffracted in a 
manner indicative of a biological molecule, but the resolution of data was not an improvement over already established 
2014 Et3i data.(12.18.2017 IWS(II) p.147) 
Figure 40 Deglycosylation of Et3i by PNGase F. The 
reaction was completed under denaturing (lanes 1-3) and 
native (lanes 5-6) conditions and visualized with a 7.5% 
acrylamide SDS-PAGE gel. (8.8.2017 IWS(II)p.56) 
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4.5 Discussion 
4.5.1 Improvements of Et3i Model Compared to Previously Published FVIII models  
This is the highest resolution structure of B-domain deleted (BDD) FVIII to date. The improved 
resolution of 3.2 Å compared to previously published models at 3.7 Å or 3.98 Å (2R7E103 and 
3CDZ104, respectively) allowed for more confidence in structural modeling and distribution of 
surface electrostatic charge (Figure 42, Figure 43). The correction of two amino acid register errors 
in the A2 domain at residues Q645 and S654 resulted in significant reassignment of the solvent 
accessible residues and surface charge of the A2 domain (Figure 44). Additionally, the metal 
chelation sites were improved at H316-H318 (Figure 45). Overall, a more robust model geometry, 
significantly lower Ramachandran and rotamer outliers, and lower Rfree have been achieved in this 
model.  
Figure 42 Comparison of Et3i and Improved hFVIII to Previous Model. Amino acid register corrections were 
primarily performed in the A2 domain. A significant improvement in the apparent secondary structure for Et3i and new 
hFVIII models was observed compared to previous FVIII structures. 
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Figure 43 Comparison of Surface Electrostatics between Et3i and hFVIII Models. Surface charge calculations were 
accomplished using PDB2PQR and visualized with APBS software (blue = positive charge, red = negative charge). 
A significant electrostatic difference was observed in the FVIII A2 domain  
Figure 44 A2 Domain Amino Acid Register Improvement. The enhanced resolution of the Et3i crystal in comparison 
to previous hFVII models corrected an amino acid register error which propagated for 55 residues in the A2 domain.  
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4.5.2 Conformational Change of Et3i C2 Domains 
The conformational movement of the C2 domain between the Et3i molecule A and B is the first 
observed in FVIII models. The C2 domain, in conjunction with the C1 domain, plays a major role 
in binding phosphatidylserine (PS) rich surfaces of activated platelets localized to the site of 
vascular injury. Previously, only small 
conformational movement within the C2 
domains of FVIII and FV had been reported 
(Figure 46).26 In FVIII, a β-hairpin loop 
containing residues M2199 and F2200 
displayed a 5 Å movement. In FV, a β-hairpin 
turn (W2063, W2064) of the C2 domain 
undergoes a 12 Å motion from a “closed” to 
“open” position. This motion is hypothesized to 
Figure 45 Cu binding site in ET3i. His317, Met321, Cys 311, and His268 appear to coordinate Cu2402. Ile313 
appears to provide steric support to the metal binding site. 
Figure 46 Previously Published C2 Domain 
Conformation Shifts. Previous conformations of the C2 
domain involved restrained movement of distal β-hairpin 
loops. (Spiegel and Stoddard, 2002) 
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play a role in binding PS-rich platelet surfaces and the conformational shift relies on FV’s unique 
flexibility granted by the steric freedom of residue G2065. In comparison, at residue 2065 FVIII 
contains alanine instead of glycine and is not thought to be sterically capable of a similar movement.  
Instead of β-hairpin loops, the conformations observed between the Et3i C2 denoted whole 
C2 domain rotation within the cup interface of the adjacent C1-A1 domains. While this movement 
could simply be a result of the low interdomain interactions of the C2 pocket as described,104 this 
whole domain shift could allow for more advantageous platelet surface interactions.  
Context for the whole C2 domain shift 
can be provided by consideration of published 
literature. In 2013, Walter et al. communicated 
the molecular structure of hFVIII C2 domain in 
complex with two anti-C2 domain antibodies 3E6 
and G99 (PDB: 4KI596) (Figure 47). In 2015, Brison et al. communicated that 3E6 antibody 
abrogated C2 binding to PS-rich lipid surfaces. From this, an updated model for residues involved 
in PS binding was proposed, including C2 domain residues R2215, K2183, and F2200 (Figure 
48).98 Based upon this new PS binding model, the C2 domain’s 3E6 epitope can be interpreted as 
analogous to a PS-rich surface plane of an activated platelet where FVIIIa binds during hemostasis. 
Figure 47 Molecular Depiction of hFVIII C2 Domain 
in Complex with 3E6 and G99 antibody Fabs. 
(Walter et al., 2013)  
Figure 48 Brison et al. 3E6 Antibody Abrogates PS Binding and New PS Binding Model. (LEFT) The nullification of 
A405 indicating C2 phosphatidylserine lipid binding was assessed by ELISA. (RIGHT) Brison et al. proposed a new 
model implicating 3E6 epitope C2 residues as necessary for lipid binding (Brison et al., 2015)  
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A superposition of the Et3i Molecule A and Molecule B into the Walter et al. anti-C2 
ternary antibody structure highlights the effect the whole domain C2 conformational shift has on 
the relative distance of the C1 domain from the analogous 3E6 binding epitope (Figure 49). Based 
on this hypothesis, the observed conformations of the C2 domain could contribute advantageous 
flexibility of the FVIIII molecule to bind to PS-rich surfaces.  
4.5.3 Crystallization of Et3i  
It was attempted to repeat the conditions that successfully yielded the Et3i crystals from 2014, but 
these attempts and further optimizations were not successful in creating a crystal that diffracted 
better than what has already been obtained. Although the model of Et3i has been refined, the 
structure of Et3i in complex with inhibitory antibodies such as G99 is of substantial interest. 
Therefore, improvements to Et3i crystal conditions remain a high priority. Crystal trays of Et3i and 
G99 were attempted but yielded only weakly diffracting crystals. 
To remove dynamic carbohydrate ligands, Et3i was treated with PNGase F. Treatment to 
remove glycans from Et3i with PNGase F was apparent under denaturing conditions, but less 
conclusive in native conditions. Further optimization and investigation of the native condition Et3i 
Figure 49 C2 Domain Conformation Shift in Context with 3E6. The Et3i A and B molecules are shown superimposed 
into the previously published anti-C2 ternary complex (Walter et al., 2013, PDB:4KI5). In the B molecule, the PS-
binding C1 domain of FVIII is brought closer to the 3E6 binding face of C2.  
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is warranted before use in crystal trials. For future crystallization attempts, including those of 
Et3i:G99, additional preparatory steps are likely warranted, including size exclusion 
chromatography of the protein complexes, and additional crystallization conditions and methods.  
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Conclusion 
Isolated C1 Domain of FVIII in Complex with Inhibitory Antibodies 
Noteworthy progress has been made towards the production and purification of the FVIII C1 
domain from a bacterial vector. Additionally, anti-C1 Fabs were successfully produced on-site from 
murine hybridomas. Initial crystallographic screening of C1:Fab complexes have yet to yield 
protein crystals capable of X-ray diffraction, but the morphology of microcrystals and phase 
separation observed in hanging-drop vapor diffusion trials is promising. 
While opportunities exist to enhance the yield and purity of our recombinant or mammalian 
culturing procedures, the project has arrived at a point where the optimization of crystallographic 
conditions for the C1:Fab complex is of priority. From the project’s current position, a protein 
crystal and subsequent molecular model could feasibly be obtained in short order. 
This project established the ability for the Spiegel lab to perform mammalian cell culturing 
in-house at Western Washington University. This capacity opens new avenues for future research 
with more complex FVIII structural targets, including current preliminary work with a complete 
porcine sequence FVIII, “POL1212” (a gift from the Lollar lab, Emory University).  
In the near term for hemophiliacs, prophylactic infusions of replacement FVIII will remain 
the therapeutic mainstay. However, for those ~30% of patients who develop an inhibitor, the ITI 
procedure is expensive, reversible and not an ideal long-term solution. Ultimately, knowledge of 
the immunogenic epitopes for FVIII is of principle importance. Continued X-ray crystallographic 
studies of FVIII in complex with inhibitory antibodies could create a comprehensive topographic 
map of immunogenicity. This information could direct development of engineered FVIII proteins 
with reduced inhibitor response. In the not-too-distant future, engineered low-immunogenicity 
FVIII constructs could be implemented in human gene therapy, effectively curing this devastating 
disease that has afflicted humankind throughout history. 
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Structure Determination of Et3i and Improvements to the human FVIII model 
As a protein candidate for ITI campaigns, the human/porcine chimeric FVIII construct “Et3i” has 
demonstrated augmented expression and activity in vivo relative to wildtype hFVIII. At 3.2 Å, the 
Et3i structure is the highest resolution model of FVIII to date. The improved model delivers an 
increased validity of molecular geometry and reassigns the amino acid register of ~70 residues in 
the A2 domain. As a result, the surface electrostatics of the protein are substantially updated and 
may hold clues to the future elucidation of molecular interactions. 
 Assessment of the two Et3i molecules observed in the crystallographic asymmetric unit 
revealed a conformational change between the C2 domains. This novel whole-domain movement 
could have substantial physiological implications in the context of FVIII binding 
phosphatidylserine-rich activated platelet surfaces.  
 The Et3i model’s porcine A1 and A3 domains were mutated in silico to the human 
sequence to generate a superior human FVIII (hFVIII) model. The novel Et3i-derived hFVIII model 
demonstrated improved model accuracy when compared to prior hFVIII structural data. Both the 
Et3i and enhanced hFVIII models will provide a more sophisticated molecular foundation from 
which to understand FVIII’s activity in hemostasis. Furthermore, continued attempts to crystallize 
Et3i with anti-C1 or anti-C2 antibodies could further expound the specific FVIII residues that 
mitigate the immunogenic response, docking to activated platelet surfaces, or binding to von 
Willebrand Factor. 
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Appendix A 
C1 IMAC Cation Optimization Purification Chromatograms 
 
 
 
Figure 50 C1 fusion Co(II) IMAC purification. The UV absorbance (blue) detected protein in the flow through, but 
following the elution step (green vertical band), no substantial protein peak eluted. (3.17.2017 IWS(I)p.138) 
Figure 51 C1 fusion Cu(II) IMAC purification. The UV absorbance (blue) detected protein in the flow through, but 
following the elution step (green vertical band), only a small protein peak eluted. This peak was not resolved on an 
SDS-PAGE gel. (3.17.2017 IWS(I)p.138) 
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Figure 52 C1 fusion Fe (III) IMAC purification. The UV absorbance (blue) detected protein in the flowthrough, but 
following the elution step (green vertical band), an unexpected large UV signal was detected. (3.17.2017 IWS(I)p.138) 
Figure 53 C1 fusion Ni(II) IMAC purification. The UV absorbance (blue) detected protein in the flowthrough, but 
following the elution step (green vertical band), no substantial protein peak was detected. (3.17.2017 IWS(I)p.138) 
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Figure 54 C1 fusion Zn(II) IMAC purification. The UV absorbance (blue) detected protein in the flowthrough, but 
following the elution step (green vertical band), a large UV signal was detected. (3.17.2017 IWS(I)p.138) 
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Appendix B 
Biolayer Interfereometry of C1 and anti-C1 Mabs 
 
Figure 55 Biolayer Interferometry (BLI) C1 Titration & "Group A" Mab M6143 [300 nM]. 
 
Figure 56 BLI Titration of C1 & "Group A" Mab 2A9 [300 nM]. The 2A9 [600 nM] condition was poorly behaved and 
is omitted from this figure. 
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Figure 57 BLI Titration of C1 & "Group B" Mab B136 [300 nM]. 
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